[COMPANY_001] Page 2
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Table of contents
Table of contents ................................................................................................................. [ADDRESS_443614] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 11
Amendment 2 ........................................................................................................................... 12
Amendment 1 ........................................................................................................................... 12
Protocol summary ..................................................................................................................... 15
1Introduction ....................................................................................................................... 19
1.1 Background ............................................................................................................ 19
1.2 Purpose .................................................................................................................. 21
2Study  objectives and endpoints ......................................................................................... 22
2.1 Primary  objective(s) ............................................................................................... 22
2.2 Secondary  objective(s) ........................................................................................... 22
2.3 Exploratory  objectives ........................................................................................... 22
2.4 Objectives and related endpoints ........................................................................... 22
3Investigational plan ........................................................................................................... 24
3.1 Study  design ........................................................................................................... 24
3.2 Rationale for stud y design ..................................................................................... 29
3.3 Rationale for dose/regimen, route of administration and duration of treatment.... 32
3.4 Rationale for choice of comparator ....................................................................... 33
3.5 Purpose and timing of interim anal yses/design adapt ations .................................. 33
3.6 Risks and benefits .................................................................................................. 33
4Population .......................................................................................................................... 35
4.1 Inclusion criteria .................................................................................................... 35
4.2 Exclusion criteria ................................................................................................... 35
5Treatment ........................................................................................................................... 38
5.1 Study  treatment ...................................................................................................... 38
5.1.1 Investigational and control drugs .......................................................... 38
5.1.2 Additional treatment .............................................................................. 39
5.2 Treatment arms ...................................................................................................... 39
5.3 Treatment assignment and randomization ............................................................. 39
5.4 Treatment blinding ................................................................................................. 40
5.5 Treating the patient ................................................................................................ 40
5.5.1 Patient numbering ................................................................................. 40

[COMPANY_001] Page 3
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
5.5.[ADDRESS_443615] -study  treatment .......................................... 47
5.6.2 Discontinua tion of study  treatment ....................................................... 47
5.6.3 Withdrawal of informed consent ........................................................... 48
5.6.4 Loss to follow -up .................................................................................. 49
5.6.5 Early study termination by [CONTACT_456] ................................................. 49
6 Visit schedule and assessments ......................................................................................... 49
6.1 Information to be collected on screening failures .................................................. 55
6.2 Patient demographics/other baseline characteristics ............................................. 55
6.3 Treatment exposure and compliance ..................................................................... 55
6.4 Efficacy .................................................................................................................. 55
6.4.1 Cognitive function assessment by  [CONTACT_356219] ................................................ 55
6.4.2 Individual cognitive domains................................................................ 57
57
6.4.4 Instrumental activities of daily  living as assessed by  [CONTACT_356220] ............................................................................ 57
6.4.5 Appropriateness of efficacy  assessments .............................................. 57
6.5 Safety ..................................................................................................................... 59
6.5.1 Brain amy loid PET imaging .................................................................. 59
60
6.5.3 Plasma beta- amyloid............................................................................. 60
6.5.4 Cardiovascular events ........................................................................... 60
6.5.5 Physical examination ............................................................................ 60
61
6.5.7 Height and weight ................................................................................. 61
61
6.5.9 Pregnancy  and assessments of fertility ................................................. 63
63

[COMPANY_001] Page 4
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
6.5.11 Appropriateness of safety  measurements .............................................. 64
6.6 Other assessments .................................................................................................. 64
64
6.6.2 Resource utilization ............................................................................... 65
6.6.3 Pharmacokinetics .................................................................................. 65
65
7Safety  monitoring .............................................................................................................. 66
7.1 Adverse events ....................................................................................................... 66
7.2 Serious adverse events ........................................................................................... 68
7.2.1 Definition of SAE ................................................................................. 68
7.2.2 SAE reporting ........................................................................................ 69
7.3 Liver safety  monitoring ......................................................................................... 69
7.4 Renal safet y monitoring ......................................................................................... 70
7.5 Cognition safet y monitoring .................................................................................. 70
7.6 Reporting of stud y treatment errors including misuse/abuse ................................ 70
7.7 Pregnancy  reporting ............................................................................................... 71
71
8Data review and database management ............................................................................. 72
8.1 Site monitoring ...................................................................................................... 72
8.2 Data collection....................................................................................................... 73
8.3 Database management and quality  control ............................................................ 73
8.4 Data Monitoring Committee .................................................................................. 74
74
9Data analy sis...................................................................................................................... 74
9.1 Analy sis sets .......................................................................................................... 75
9.2 Patient demographics and other baseline characteristics....................................... 75
9.3 Treatments ............................................................................................................. 76
9.4 Analy sis of the primary  variable(s) ....................................................................... 76
9.4.1 Variable(s) ............................................................................................. 76
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 77
9.4.3 Handling of missing values/censoring/discontinuations ....................... 78
9.4.4 Sensitivity  analy ses............................................................................... 79
9.5 Analy sis of secondary  variables ............................................................................ 80
9.5.1 Efficacy  variables.................................................................................. 80
9.5.2 Safety variables ..................................................................................... 80
9.5.3 Resource utilization ............................................................................... 82

[COMPANY_001] Page 5
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
9.5.4 Pharmacokinetics .................................................................................. 82
82
9.5.6 Biomarkers ............................................................................................ 83
9.5.7 PK/PD ................................................................................................... 83
83
83
83
9.7 Interim anal yses..................................................................................................... 86
9.8 Sample size calculation.......................................................................................... 86
9.8.1 Sample size calculation for the primary  endpoint ................................. 86
9.8.2 Sample size calculation for the PET imaging substudy ........................ 86
9.8.3 Blinded sample size re- estimation ........................................................ 87
10Ethical considerations ........................................................................................................ 87
10.1 Regulatory and ethical compliance ........................................................................ 87
10.2 Informed consent procedures................................................................................. 87
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 88
10.4 Publication of study  protocol and results ............................................................... 88
10.5 Quality  control and quality  assurance .................................................................... 88
11Protocol adherence ............................................................................................................ 89
11.1 Protocol amendments ............................................................................................. 89
12References ......................................................................................................................... 89
94
14Appendix 2: L iver event definition and follow -up requirements ...................................... 95
15Appendix 3: Treatment guidelines for h yperkalemia (serum potassium greater than 
or equal to 5.3 mmol/L  [mEq/L ])...................................................................................... 97
16 Appendix 4: Guidelines for the management of blood pressure ....................................... 99
17Appendix 5: Guidel ines for the management of renal dysfunction ................................. [ADDRESS_443616] of tables
Table 2 -1 Objectives and related endpoints .......................................................... 22
Table 3 -1 Minimum pre -study  total daily  doses of commonly  used ACEis and 
ARBs allowing patients to begin the treatment run -in epoch at Visit 
102 (valsartan 80 mg bid) ..................................................................... [ADDRESS_443617] be met at Visit 1 (screening), 
Visit 103 and Visit 199/201 .................................................................. 27
Table 3 -3 Study  drug dose levels during randomized treatment epoch ................ 28
Table 5 -1 Study  drug dispensed for the tr eatment run -in epoch by  [CONTACT_154023] .....42

[COMPANY_001] Page 6
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Table 5 -2 Study  drug dispensed during the randomized treatment epoch by  
[CONTACT_154023] .............................................................................................. 42
Table 5 -3 Prohibited treatment .............................................................................. 45
Table 6 -1 Assessment schedule ............................................................................. 51
62
Table 7 -1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... [ADDRESS_443618] of figures
Figure 3-1 Study  design .......................................................................................... 25
Figure 3 -2 Treatment run-in epoch overview ......................................................... 26

[COMPANY_001] Page 7
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
List of abbreviations
Aβ Amyloid beta
ACE(i) Angiotensin converting enzy me inhibitor
AD Alzheimer’s disease
ADAS -Cog Alzheim er’s disease assessment scale -cognitive subscale
ADNI Alzheimer’s disease neuroimaging initiative
AE Adverse event
AESI Adverse event of special interest
Alb Albumin
ALT Alanine aminotransferase
ANCOVA Analysis of covariance
APOE [ADDRESS_443619]
DM Diabetes mellitus
DMC Data monitoring committee
 

[COMPANY_001] Page 8
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Echo Echocardiography
eCRF Electronic case report form
EDC Electronic data capture
eGFR Estimated glomerular filtration rate
ENR Enrolled set run -in phase
EOS End of study
EOT End of treatment
FAS Full analy sis set
FAQ Functional activities questionnaire
FLAIR Fluid attenuated inversion recover y
FSH Follicle stimulating hormone
GCCS Global cognitive composite score
GCP Good Clinical Practice
GMLT Groton maze learning test
γGT Gamma -glutam yl transferase
HF Heart failure
HFpEF Heart failure and preserved ejection fraction
HFrEF Heart failure and reduced ejection fraction
HIV Human immunodeficiency virus
HTN Hypertension
IADL Instrumental activities of daily living
IB Investigator brochure
ICF Informed consent form
ICH International council for harmonisation
IDT Identification test
IEC Independent ethics committee
IN Investigator notification
IRB Institutional re view board
IRT Interactive response technology
ISLT-DR Interactive shoppi[INVESTIGATOR_356186]696 run -in set
LV Left ventricular
LVEF Left ventricular ejection fraction
MAR Missing at random
MBq Megabecquerel
MCCB MATRICS cognitive assessment battery
MCHC Mean corpuscular hemoglobin concentration

[COMPANY_001] Page 9
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
MCI Mild cognitive impairment
MCV Mean corpuscular volume
MDRD Modification ofdiet in renal disease
MedDRA Medical dictionary for regulatory activities
MI Myocardial infarction
MID Minimally important difference
MMSE Mini mental state examination
MNAR Missing not at random
MRA Mineralocorticoid receptor antagonist
MRI Magnetic resonance imaging
NEP(i) Neutral endopeptidase inhibitor
NSAIDS Non-steroidal anti- inflammatory drugs
NT-proBNP N-terminal pro -brain natriuretic peptide
NYHA [LOCATION_001] Heart Association
ONB One back test
PCI Percutaneous coronar y intervention
PDE-[ADDRESS_443620] operating procedure
SSRI Selective serotonin reuptake inhibitor
S[LOCATION_003]R Suspected unexpected serious adverse reaction
SUVr Standardized uptake value ratio

[COMPANY_001] Page 10
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
TBL Total bilirubin
TD Study Treatment Discontinuation
TSH Thyroid stimulating hormone
ULN Upper limit normal
US CFR [LOCATION_002] code of federal regulations
VRS Valsartan run -in set
WBC White blood cell
WoC Withdrawal of Consent

[COMPANY_001] Page 11
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Glossary  of terms
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 
100mg once a day, 75 mg twice a day)
Enrollment Point/time of patient entry into the study at which informe d consent must 
be obtained (e.g. prior to starting any of the procedures described in the 
protocol)
Epoch A portion of the study which serves a specific purpose. T ypi[INVESTIGATOR_18501]: screening/recruitment, wash -out, treatment, and follow -up
Investigational drug The drug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is s ynon ymous with
“investigational new drug” or “investigational medicinal product.”
Medication pack number A unique identifier on the label of each investigational drug package
Part A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in patients/subjects
with established disease and in those wi th newly -diagnosed disease.
Patient/subject ID A unique number assigned to each patient upon signing the informed 
consent 
Randomization number A unique identifier assigned to each randomized patient, corresponding 
to a specific treatment arm assignment
Study drug/ treatment Any single drug or combination of drugs administered to the patient as 
part of the required study procedures; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy
Study Treatment 
Discontinuation (TD)When the patient permanently stops taking study treatment prior to the 
defined study treatment completion date 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to eva luate the drug being 
tested in the study
Withdrawal of consent 
(WoC)Withdrawal of consent from the study is defined as when a patient does 
not want to participate in the study any longer, and does not want any 
further visits or assessments, and does not want any further study 
related contact, and does not allow analysis of already obtained biologic 
material

[COMPANY_001] Page 12
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Amendment [ADDRESS_443621] to the numbering of the exclusion 
criteria’s that was starting at ‘2’instead of ‘1’(in the Section 4.2 Exclusion criteria ).As of 
18-Aug-[ADDRESS_443622] 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities. 
The changes described in this amended protocol are non-substantial and do not require 
IRB/IEC approval prior to implementation.
The changes herein do NOT affect the trial specific model I CF.
Amendment [ADDRESS_443623] of the inclusion and exclusion criteria 
were derived from the PARAGON -HFtrial (an event -driven trial) where they were thought 
not to impact the objectives of the CL CZ696B2320 study . 
However experience to date suggests that the observed screen failure rate in CLCZ 696B2320 
study  is considerabl y higher than originally  anticipated. Many of the failures are due to 
patients not being able to meet the magnetic resonance imaging (MRI)cerebrovascular 
criteria . The existing MRI criteria were intended to exclude patients with significant 
cerebrovascular pathology  in whom the rate of change in cognitive function over t ime may  be 
different to those without significant background vascular disease. However ,based on 
PERSPECTI VE study  screening experience as well as available literature ,the prevalence of 
cerebrovascular disease appears to be significantly  higher than origi nally anticipated and the 
existing exclusion criteria appear to limit the population to the extent that the study  cohort 
might not be truly reflective of the heart failure patients seen in the community . Therefore ,in 
the interest of keepi[INVESTIGATOR_356187] ,the amended protocol will no longer exclude cerebrovascular disease as assessed 
on the MRI criteria. Cerebrovascular disease burden will continue to be assessed as per the 
existing criteria , andthe baseline value will be used as an additional independent variable in 
the statistical analy sis modeling for the primary  and relevant secondary  endpoints .Patients 

[COMPANY_001] Page 13
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
with clinically  significant cerebral pathology , for example large cerebral aneury sm, spac e 
occup ying lesion etc. will continued to be excluded from the study .In addition, some of the 
existing criteria taken from PARAGON- HFwere originally  developed to help identify 
patients at high risk for cardiovascular events which are not relevant for theobjectives of 
CLCZ 696B2320 study . Therefore this amendment aims to revise some of the study  inclusion 
and exclusion criteria to remove unnecessary  restrictions and to ensure the study  population 
reflects the HFpEF population in the community .  In addition , this amendment also corrects 
inconsistencies between various sections of the protocol, corrects typographical errors ,and 
provides clarifications where instructions are less clear. Some of the key changes to the 
protocol are listed below.
None of the changes are expected to have major impact on the objectives or the anal ysis of the 
study  results.
Changes to the protocol
Key updates to Section 4.1 (Inclusion criteria) and Section 4.2 (Exclusion criteria):
 NT-proBNP requirement is adjusted to ≥125 pg/mL  to be consistent with new 
European Societ y of Cardiology  guidelines.
Prior heart failure hospi[INVESTIGATOR_356188] a diagnosis of heart failure in the absence 
of NT -ProBNP values of ≥ 125 pg/mL .
Remove dthe requirement to meet MRI  criteria for cerebrovascular and white matter 
lesion . Clinically  significant cerebral pathology  that may  impact cognition will remain as 
an exclusion criteri on.
Removed the existing exclusion criterion in order to allow participation of patients with a 
history  of cardiom yopathies that have an ejection fraction of >40% ; as e xclusion of these 
patients is not relevant to the study  objectives and these patients may  benefit from 
treatment with L CZ696.
Significant obstructive v alvular disease is added as an exclusionary  criterion as these 
patients are less to lerant to vasodilators .
Listedthe exclusions and restrictions regarding the use of sedative hy pnotics, selective 
serotonin re -uptake inhibitors, serotonin norepi[INVESTIGATOR_263857]- uptake inhibitors which are 
described elsewhere in the protocol but are missing fr om Section 4.1 .
Clarification provided regarding the exclusionary  criterion for th yroid function tests, 
Vitamin B12 orfolate deficiency .
Updated Sections 5.3and 6.5.[ADDRESS_443624] starting 
time.
Assessment scheduled (Table 6 -1) was updated to clarify  that the p lasma beta amy loid will be 
assessed onl y in pa tients partici pating in PET sub study .
Updated Section 6.5.1 to indicate that,theend of study  (EOS )imaging procedures will be 
performed onl y when prior assessments were made more than 12 months ago.

[COMPANY_001] Page 14
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Updated Sections [IP_ADDRESS] and 6.5.[ADDRESS_443625] typographical errors and inconsistencies in 
the protocol.  

[COMPANY_001] Page 15
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Protocol summary
Protocol number CLCZ696 B2320
Title A multicenter, randomized, double -blind, active -controlled study to 
evaluate the effects of LCZ696 compared to valsartan on cognitive 
function in patients with chronic heart failure and preserved ejection 
fraction
Brief title Study to evaluate the effect sof LCZ696 on cognitive function in patients 
with chronic heart failure (HF) and preserved ejection fraction ( pEF)
Sponsor and Clinical 
Phase[COMPANY_001], Phase [ADDRESS_443626] of LCZ696 compared to 
valsartan on cognitive function in patients with HFpEF.
Primary Objective To evaluate the effects of LCZ696 compared to valsartan on cognitive 
function over 3 years in patients wit h HFpEF as assessed by [CONTACT_356221].
Secondary Objectives To evaluate the effect of LCZ696 compared to valsartan on -amyloid 
deposition in the brain in a subset of patients using amyloid positron 
emission tomography (PET) imaging over 3 years. 
To evaluate the effects of LCZ696 compared to valsartan on individual 
cognitive domains (memory, executive function, and attention) as 
assessed by [CONTACT_356222] o ver 3 
years
To compare LCZ696 to valsartan in evaluating changes in instrumental 
activities of daily living (IADL) as assessed with Functional Activity 
Questionnaire (FAQ) over [ADDRESS_443627] of 520 patients ≥60 years of age with 
chronic sy mptomatic HF ( [LOCATION_001] Heart Association ( NYHA)class II -IV) 
andleft ventricular ej ection fraction (LVEF) > 40%.
Inclusion criteria 1.Written informed consent including consent for APOE4 gene testing 
must be obtained before any assessment is performed
2.Male or female patients aged ≥60 years of age.
3.Chronic heart failure with current sy mptom(s) (NYHA class II -IV) at 
Screening visit.
4.LVEF > 40% 
a.By [CONTACT_356223] 6 months 
prior to screening visit OR
b.By [CONTACT_356224], if 
previous assessment is not available.
5.NT-proBNP ≥ 125 pg/mL at Screening visit

[COMPANY_001] Page 16
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
6.Patient with evidence of ade quate functioning (e.g.: intellectual, motor, 
visual and auditor y) to comple te the study assessments and has 
elem entary education or 6 years of sustained employment.
Key Exclusion criteria 1.Current acute decompensated HF requiring augmented therapy with 
diuretics, vasodilators and/or inotropic drugs.
2.Acute coronar y syndrome (including myocardial infarction ( MI)), cardiac 
surgery, other major cardiovascular ( CV)surger y, or urgent 
percutaneous coronary intervention (PCI), carotid surgery or carotid 
angiopl asty, history of stroke or transient ischemic attack within the 3 
months prior to Screening visit or an electi ve PCI within 30 days prior 
to Screening visit.  
3.Patients with ahistor y of hereditar y or idiopathic angioedema or 
angioedema related to previous angiotensin converting enzy me 
inhibitor ( ACEi )or angiotensin receptor blocker ( ARB)therapi[INVESTIGATOR_014].
4.Patients who require treatment with 2 or more of the following: an ACEi, 
an AR B or a renin inhibitor.
5.Patients with one of the following:
a.Estimated glomerular filtration rate ( eGFR )<30 mL/min/1.73 m2as 
calculated by [CONTACT_36577] (MDRD) 
formula at screening visit, or
b.eGFR <25 mL/min/1.73m2at Visit 103 or at end of run -in / 
randomization visit, or
c.eGFR reduction >35% (compared to Visit 1) at Visit 103 or Visit 
199/201
6.MMSE score <24 at S creening visit 
7.Patients with a clinical diagnosis of Alzheimer’s disease or other 
dementia syndromes or any indicatio n for or current treatment with 
cholinesterase inhibitors and/or another prescription Alzheimer’s 
Disease ( AD)treatment (e.g. ,mema ntine).
8.Any history of medical or neurological condition likely to affect the 
participant’s cognition  (e.g., clinically significant brain trauma with loss 
of consciousness > 3 minutes within 6 months prior to screening, 
Huntington’s disease, Parkinson’s disease, Ly me’s disease, syphilis, 
HIV dementia, uncontrolled seizure disorder )or clinically significant 
abnormal ities in thyroid function tests, Vitamin B12 or folate deficiency 
requiring treatment at screening (Patients who are adequately treated 
may be included at investigator discretion ).  
9.Inability to perform cognitive battery or other study evaluations based 
on signif icant motor ( e.g. hemiplegia, muscular -skeletal injury) or 
sensory (blindness, decreased or uncorrected visual or auditory 
acuit y) skill.
10.Score “yes” on item 4 or item 5 of the Suicidal Ideation section of the 
Colum bia suicidality severity rating scale (C-SSRS ), if this ideation 
occurred in the past 6 months, or “yes” on any item of the Suicidal 
Behavior section, except for the “Non -Suicidal Self -Injurious Behavior” 
question, if this behavior occurred in the past [ADDRESS_443628] cognition as 
assessed by [CONTACT_356225] .
12.History of hypersensitivity to any of the study drugs or to drugs of 
similar chemical classes.
13.History or presence of any other disease with a life expectanc y of <3 

[COMPANY_001] Page 19
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
1 Introduction
1.1 Background 
Heart failure (HF) is a major public health problem associated with a high morta lity rate, 
frequent hospi[INVESTIGATOR_36651], and poor quality  of life. Despi[INVESTIGATOR_356189], heart 
failure remains a progressive syndrome with a high mortality  rate, and an illness with an 
unmet need for new therapi[INVESTIGATOR_356190] ( McMurray  et al 2012 ).
LCZ696 is an angiotensin receptor nepril ysin inhibitor (ARNI) for the treatment of patients 
with chronic heart failure and reduced ejection fraction (HFrEF). After ingestion, LCZ696 
delivers systemic exposure to sacubitril (AHU377
), a neprily sin inhibitor pro-drug, and 
valsartan, an angiotensin receptor blocker (ARB). Nepril ysin (neutral endopeptidase, ( NEP )) 
is a naturally  occurring membrane -bound enzyme, responsible for the degradation of 
natriuretic peptides and other peptide hormones such as adrenomedullin, brady kinin, 
substance P, angiotensin I and II, β-amyloid, andpossibly  endothelin -1.  LCZ696, through its 
unique mode of action potentiates beneficial endogenous vasoactive peptides via NEP 
inhibition while inhibiting the Renin Angiotensin System (RAS) via angiotensin IItype 1 
receptor blockade; both mechanisms are considered to act in a complementary  and additive 
manner to improve outcome in patients with HFrEF .
Consistent with this mechanism of action, the recently  completed landmark randomized trial
(PARADIGM -HF, N= 8442 ) demonstrated that LCZ696 was superior to enalapril (current 
standard of care) in reducing cardiovascular (CV) death and heart failure hospi[INVESTIGATOR_356191] . The magnitude of these advantages of LCZ696 over an angiotensin 
converting enzyme (ACE )inhibitor was statistically  significant and clinically  relevant , 
particularl y since the drug was compared with current standard of care with an established 
mortality  benefit in HF patients ( McMurray  et al 2014 ). In this study , compared with enalapril 
(ACE i), LCZ696 demonstrated a 20% risk reduction for HF hospi[INVESTIGATOR_356192] 
(primary  endpoint, p =0.0000002), 20% risk reduction in CV death alone (p=0. [ZIP_CODE]), and 
21% risk reduction for first HF hospi[INVESTIGATOR_059] (p=0.[ZIP_CODE]). In addition, LCZ696 also 
demonstrated benefit in symptom improvement, total HF hospi[INVESTIGATOR_059], all cause 
hospi[INVESTIGATOR_356193].   LCZ696 is currentl y under 
investigation for patients with heart failure and preserved ejection fraction (HFpEF) in an 
ongoing large randomized clinical trial (PARAGON -HF, 4600 patients with HFpEF )
, where 
nostandard of care is available .
Cognitive impairment has been reported in patients with heart failure in several studies over 
the past three decades.  The prevalence of cognitive impairment observed in these heart failure 
studies (no distin ction made between HFrEF or HFpEF) ranged from 25 to 75% ( Ampadu and 
Morley  2015, Cannon et al 2015 ). Changes in cognition as a result of improved cardiac 
function have notbeen extensiv ely evaluated.  However, studies in heart failure patients 
implanted with a left ventricular assist device showed that cognition, as assessed by a 
comprehensive battery  of tests, was improved during follow -up ranging from 6 months to 2 
years (Simoni et al 2014 ).  

[COMPANY_001] Page 20
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Observational epi[INVESTIGATOR_356194] a relationship between cognitive 
impairment and elevated blood pressure (BP).  For example, the Honolulu -Asia Aging Study 
revealed that systolic blood pressure in midlife was associated with cognitive impairment later 
in life (Launer et al 2000 ).  In another longitudinal study  that followed elderl y patients in 
Sweden, an association was shown betwe en blood pressure at age 70 and the subseq uent 
development of dementia 10 to 15 years later (Skoog et al 1996 ). Thus, a reasonable 
expectation would be that antihy pertensive therapy  should slow cognitive decline. However, 
the effect of blood pressure lowering on cognition, although extensively  studied, has yielded 
inconsistent findings.  These conflicting results are likely due to the use of different study 
designs, varying baseline blood pressures, inconsistent inc lusion criteria, and most 
importantly , inadequate power to detect meaningful responses (Gorelick and Nyenhuis 2012 ).   
Nevertheless, it is therefore possible that an improvement in cardiac function and blood 
pressu re per se , as a result of long -term drug treatment, with L CZ696, may result in beneficial 
effects on cognition.
Cognitive decline is also observed in patients with a history  of stroke or vascular disease 
detected by [CONTACT_95425]. Cognitive impairment assoc iated with cerebrovascular dysfunction 
is classified as “vascular cognitive impairment” (Gorelick et al 2011 ).  In contrast, cognitive 
functional changes that are evident in Alzheimer’s Disease (AD) are associated with beta 
amyloid(Aβ)neuritic plaques and neurofibrillary  tangles. These two conditions (deposition of 
neuritic plaque and changes in cerebrovascular structure and function) can exist concurrentl y
in elderl y patients and is now being described as one entity,known as “mixed dementia”.  
Moreover, there is likely a complex interplay  between the pathological processes leading to 
these various dementias.
Alzheimer’s disease is a complex, multifactorial disease that develops over a long period of 
time (15-20 
years), and is associated with the presence of amyloid beta (Aβ) plaques in the 
brain. The Aβ42 isoform is primarily  found in amyloid plaques, whereas the Aβ40 isoform is 
primarily  found in amy loid angiopathy  (Mawuenye ga et al 2010 ). In addition to degrading the 
biologicall y active vasoactive peptides mentioned above, in vitro and non-clinical studies 
have shown that neprily sin is one of multiple enzy mes involved in the proteoly tic degradation 
of Aβ. Other proteases with Aβ-degrading properties include insulin -degrading enzyme, 
endothelin -converting enzyme, ACE, and plasmin (Wang et al 2006 )
. Besides enzymatic 
degradation of Aβ, it is also removed from the brain by [CONTACT_356226][INVESTIGATOR_872] (CSF) and the bloodstream (Saido and Leissring 2012 ). The relative 
importance of each of these pathway s for proteoly tic degradation of Aβ in humans is 
unknown ,but nepril ysin inhibition could potentially  reduce the clearance of Aβ from the 
central nervous system (CNS) . Reduced clearance of Aβ from the brain over a prolonged 
period of time could theoreticall y result in an accumulation of Aβ in brain parench ymal 
plaque, which may  increase the risk of development of AD.  
To 
gain a better understanding of the impact of neprily sin inhibition on Aβ metabolism , a 2-
week study  in young cynomolgus monkey s (2-4 year old) was undertaken, and Aβ 
concentrations in CSF and brain tissue were assessed during treatment with LCZ696. The
dosing regimen (50 mg/kg /day) in the monkey  resulted in a systemic drug exposure similar to 
LCZ696 400 mg once daily  dosing in man. In this study , LCZ696 treatment resulted in an 
acute decrease in clearance of CSF Aβ42 on D ay 1, and increase in total CSF Aβ42 and Aβ38 

[COMPANY_001] Page 21
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
on D ay 15. It is important to note that by [CONTACT_2006] [ADDRESS_443629] s other than neprily sin may  be importa nt in clearance of 
CSF Aβ in humans.
In a chronic toxicology  study  in cy nomolgus monkey s treated with LCZ696 at 300 mg/kg/day 
for 39 -weeks, there were no increases in brain immunostaining for Aβ42, plaque formation, or 
compound -related microscopic brain changes. This 300 mg/kg/day  dose in mon keys resulted 
in an approximately  10-fold greater maximum concentration ( Cmax )in plasma than a [ADDRESS_443630] of care. The age of patients in 
PARADIGM -HF was 63.8 ± 11.5 (mean ± SD). Similarly , in the 36 week PARAMOUNT 
study  in patie nts (70.9 ± 9.4 years of age) with HFpEF, there was no increased incidence of 
AD or dementia -related adverse events in LCZ696 -treated patients compared to patients 
receiving valsartan. However, these studies were not prospectively  designed to specificall y 
evaluate the effect of LCZ696 on AD or dementia.
The overall net effect of these various factors on cognition has not been specificall y studied . 
For example, the potential long-term effects on the clearance of Aβ as a result of nepril ysin 
inhibition via LCZ696 and potential cognitive benefit derived from improved cardiac and 
hemody namic function as a result of chronic LCZ696 treatment remain unknown. The 
primary  goal of the current study  is to assess the overall impact of long -term LCZ696 therapy
compared to valsartan on cognitive function assessed via a comprehensive battery  of 
neurops ychological tests in patients with HFpEF. In addition, β-amyloid deposition in brain 
will be assessed using positron emission tomography  amyloid (PET) imaging.
1.[ADDRESS_443631] of LCZ696 therapy  compared to valsartan on amy loid plaque deposition 
in the brain will be evaluated in a subset of patients using amyloid florbetapir 18FPET
imaging.

[COMPANY_001] Page 24
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Objective Endpoint Analysis
[ADDRESS_443632] of LCZ696 compared to valsartan on cognitive function 
as assessed by a comprehensive cognitive battery  in patients with HFpEF (Figure 3-1). The 
study  population will consist of patients ≥60 years of age with chronic symptomatic HF 
(NYHA class II-IV)and a left ventricular ejection fraction (LVEF) >40% . Patients will be 
randomized in a 1:1 fash ion to either L CZ696 200 mg bid or valsartan 160 mg bid.
Cognitive function will be assessed at baseline and every  six months up to 3 years by a 
comprehensive cognitive battery ,and MMSE will be assessed annually . Patients scoring <24 
on the MMSE scale during screening will be excluded from the study . Patients will be 
stratified based on age (< 75, ≥ 75 y ears) , MMSE score (< 28, ≥ 28), and if participating in the 
PET imaging substudy , amyloid status (amyloid posit ive/negative). APOE 4is a strong 
predictor of cognitive impairment ( Lim et al 2015 ) and Aβ accumulation. Therefore, patients 
will be genot yped for APOE [ADDRESS_443633] of LCZ696 therapy  compared to valsartan on -
amyloid deposition in the brain using florbetapir18FPET imaging in a subset of patients. PET 
imaging requires specialist centers experienced in the technique that are in close proximity  to 
a radiopharmaceutical production facility , thus a subset of centers will be selected as PET 
centers. To ensure high quality  of imaging data, PET imaging will be conducted in all eligible 
patients at selected PET capable centers. Amyloid PET imaging will be performed at 
randomi zation, at 18 months ,and at 3 years
(EOS Visit ). If a patient permanently  discontinues 
treatment prior to 3 years, a PET scan should be done at theend of treatment visit (EOT visit) 
if a prior scan was performed more than twelve months ago. End of study  (EOS) scan will not 
be required if EOT scan is performed within 12 months of end of study  visit. All PET scans 
will be evaluated centrally.
Brain magnetic resonance imaging (MRI )will be performed at the Screening visit in all 
patients to evaluate exclusion criteria , at 18 months , attheend of treatment visit (EOT Visit, 
only if prior scans were performed more than twelve months previously ),and at the end of 
study  visit.With the exception of the screening MRI, subsequent MRI scanswill only be 
performed in the sub-set of study  patients for which PET is being performed . All MRI scans 
will be evaluated centrally .  Baseline MRI scans at screening will assist in determining patient 
eligibility  for the study .  Magnetic resonance images will also be used to assess global and 
regional brain structural volume at baseline and at end of study . 

[COMPANY_001] Page 25
Amended Clinical Trial Protocol Version 0 2  (Clean) Protocol No. CLCZ696B2320
Figure 3-1 Study  design
bid –twice daily dosing
Screening epoch
A Screening e poch of approximately  3weeks will be used to assess eligibility . 
To minimize unnecessary patient assessment burden ,sites are strongl y advised to administer 
Cognitive assessments (MMSE,  FAQ,  CCB) only after confirming that the 
screening laboratory  data are available and the patient is considered otherwise eligible to 
participate in the study . Cognitive assessments should ideally  be administered by [CONTACT_356227] a quiet environment and prior to any other clinical assessments scheduled during 
the day. The investigator must ensure patient eligibility  on all inclusion/exclusion criteria 
including laboratory  and MMSE assessments prior to performing the MRI scan. It takes up to 
five days toconfirm eligibility  from the central MRI reader. The sites should take this into 
consideration when scheduling MRI scans.
A patient who enters screening but is determined not to be eligible to enter the treatment run-
in period will be considered a screen failure. The investigator may consider re-screening the 
patient at a later time if he/she believes that the patient’s condition has changed and may 
potentially  be eligible. A minimum of [ADDRESS_443634] screen failed based on MRI criteria 
for cerebral and vascular pathology  in the original protocol may be eligible to be rescreened 
after implementation of protocol amendment 1. In those patients if previous study  MRI scan 
was performed within 6 months of re-screening date this will be considered baseline 
assessment for th ese patients and no further baseli ne scans will be acquired .

[COMPANY_001] Page 26
Amended Clinical Trial Protocol Version 0 2  (Clean) Protocol No. CLCZ696B2320
Single -blind treatment run -in epoch
The single -blind treatment run-in period is designed to assess patient’s tolerability  to study 
drug, and to determine patients who are likely  to stay on study  drug for the duration of the 
trial. 
The treatment run-in period consists of valsartan 40 mg bid(if necessary ), followed by 
[CONTACT_356228] 80 mg b
idand then followed by [CONTACT_356229]696 100 mg bid, over 3to 8 weeks duration 
(Figure 3-2). During the run-in period, patients will continue their background HF 
medica tions with exception of ACEi, ARB or renin inhibitor which will be discontinued. The 
concomitant use of ACEi, ARB or renin inhibitor during the treatment run-in is strictly  
prohibited. Patients will enter the treatment run-in period based on their use of RAS blockade 
medications at the time of screening (Figure 3-2and Table 3-1).  Patients unable to tolerate 
either valsartan or LCZ6 96 during the run-in will not be eligible for randomization, and will 
be discontinued from the study . This design will allow a careful assessment of the patient’s 
tolerability  to study  medications prior to randomization. 
Patients will enter different parts of the treatment run-in period based on their use of RAS 
blockade medications at the time of enrollment. Patients should enter the treatment run-in 
period at Visit [ADDRESS_443635] been on an ACE ior ARB 
medication at a dose which is equivalent toor above the total daily  doseslisted in Table 3-1.
Otherwise, patients should enter the treatment run -in epoch at Visit 101 starting with valsartan 
40 mg bid for 1to 2 weeks before they  start valsartan 80 mg bid at Visit 102. However, at the 
investigator’s discretion, those patients who are on ACE ior ARB medication at equivalent to 
or above the total daily dose listed in Table 3-1can also enter the treatment run-in epoch at 
Visit 101 starting valsartan 40 mg bid.
Figure 3-2 Treatment run -in epoch overview
bid –twice daily dosing

[COMPANY_001] Page 27
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Table 3-1 Minimum pre -study total daily  doses of commonly  used ACE is and 
ARBs allo wing patients to begin the treatment run -in epoch at Visit 
102(valsartan 80 mg b id)
ACEI Dose ARB Dose
Benazepril 20 mg Azilsartan 40 mg
Captopril 100 mg Candesartan 16 mg 
Cilazapril 2.5 mg Eprosartan 400 mg 
Enalapril 10 mg Irbesartan 150 mg 
Fosinopril 20 mg Losartan 50 mg 
Imidapril 10 mg Olmesartan 10 mg 
Lisinopril 10 mg Telmisartan 40 mg 
Moxepril 7.5 mg Valsartan 160 mg 
Perindopril 4 mg 
Quinapril 20 mg 
Ramipril 5 mg 
Trandolapril 2 mg 
Zofenopril 30 mg
Patients who meet the safet y monitoring criteria (Table 3-2) at Visit 103 will proceed to 
treatment with L CZ696 100 mg bid for 2 to 4 weeks.
Study  drug should not be dispensed unless the patient meets all inclusion criteria and none of 
the exclusion criteria at Visit 1 and subsequently  at Visit 199/[ADDRESS_443636] be met at Visit 1 (screening), Visit 
103 and Visit 199/201
Parameter Visit 1 (Screening)Visits 103 (treatment run -in) and Visit 199/201 
(end of treatment run -in/randomization)
Potassium level K ≤5.2 mmol/L (mEq/L) K ≤5.4 mmol/L (mEq/L)
Kidney function eGFR ≥30 mL/min/1.73m2eGFR ≥25 mL/min/1.73m2
eGFR reduction <35% compared to Visit 1 
Blood pressure SBP ≥110 mmHg No sy mptomatic hypotension as determined by 
[CONTACT_356230] ≥100 mmHg.
AEs or conditions No conditions that preclude 
continuation according to 
the investigator’s judgmentNo postural s ymptom s or any AEs that preclude 
continuation according to the investigator’s 
judgment
AE –adverse event
To assess the patient’s eligibility  to continue in the study , either local or central laboratory 
should be used for the assessment of potassium and e stimated glomerular filtration rate (e GFR )
at Visits 103 and 199/201 (end of treatment run-in visit/randomization ). If central laboratory 
is used, since itmay take up to 72 hours to obtain the results, it is recommended that the site 
take this into consid eration when scheduling subsequent study  visits, while keepi[INVESTIGATOR_356195].  If a local laboratory  is selected, the same samples should 
also be sent to the central laboratory , while the evaluation should be solely based on the local
laboratory  results.  Patients should NOT enter Visits 103 or 199/201 without evaluating the 
safet y monitoring criteria ( Table 3 -2).  

[COMPANY_001] Page 28
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Down -titration of study  drug is not allowed during the treatment run-in period. Patients who 
are not able to tolerate study  drug at the doses prescribed during the treatment run-in epoch 
will be discontinued. 
Investigators may consider adjusting (dose reduced or discont inued) background medications 
(e.g., diuretic(s), antihy pertensive agents, cardiovascular medications such as beta blockers,
MRAs ,nitrates ,etc.) if the study  drug is not tolerated (e.g., occurrence of AEs such as 
hyperkalemia, hypotension, and renal dysfunction) to ensure patients meet the safet y criteria 
in Table 3-2during the treatment run-in epoch.  Patients may be seen at any time for 
unscheduled visits during the treatment run-in epoch for re-evalu ation of safet y criteria 
parameters. 
Patients who experience angioedema at any time during the treatment run-in epoch must be 
discontinued from the study . 
Patients who are discontinued from the treatment run-in epoch due to intolerance to the study  
drug, development of angioedema or for failure to meet the specified safety  criteria will be 
considered treatment run -in failures and are not eligible to be re- screened for study  entry .
At the end of the treatment run-in epoch (Visit 199/201), patients who meet the safety  criteria 
(Table 3-2) and tolerate LCZ696 [ADDRESS_443637] 2 weeks are eligible for 
randomization . For these patients, Visit 199 and 201 occu rsover a period of multiple days.  
Patients should be instructed not to take their morning (am) dose of treatment run-in study 
drug on the day  they  start randomized study  drug.
Randomized treatment epoch
At randomization (Visit 199/201), eligible patients will be randomized to 1 of 2 treatme nt 
arms, either LCZ696 200 mg bid or valsartan 160 mg bi d in a 1:1 fashion.
Every  attempt should be made to maintain patients on the target study  drug dose (dose level 3) 
(Table 3 -3) throughout the trial. I fthe patient does not tolerate the target study  drug dose level 
the investigator should consider, if appropriate, adjusting background medications to rectify 
the situation before considering down -titration to the next lower study  drug dose level 
(Section 5.5.5 ).
Table 3
-3 Study  drug dose levels during randomized treatment epoch
Dose level LCZ696 Treatment A rm Valsartan Treatment A rm
3 200 mg bid 160 mg bid
2 100 mg bid 80 mg bid
1 50 mg bid 40 mg bid
At each dose level the patient will also take matching placebo for the other treatment arm 
study  drug.
Study  drug dose level adjustments should be based on overall safet y and tolerability  with 
special focus on a) hyperkalemia, b) symptomatic hypotension, and c) clinically  significant 
decrease in eGFR/increase in serum creatinine (SCr) . Treatment guidance for hyperkalemia, 
management of BP, and renal dysfunction are provided in Appendix 3, Appendix 4, and 
Appendix 5 ,respectivel y.

[COMPANY_001] Page 29
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
3.2 Rationale for study  design
The key study design features of this study , including the run-in period, target dose, 
comparator and dose selection are largel y similar to the current ongoing PARAGON -HF
study  (CLCZ 696D2301) which is a Phase [ADDRESS_443638] ementary  to the data from the PARAGON -HF study .
Study Population: 
The study  population will consist of patients 60 years and older with chronic heart failure 
(NYHA class II-IV)and LVE F > 40%. LCZ696 has been shown to improve survival and 
reduce heart failure -related hospi[INVESTIGATOR_356196] (LVEF ≤40%). Hence the 
study population consists of patients with HFpEF (LVEF >40%), as it is considered unethical 
to randomize HFrEF patients in this long term study  to the valsartan treatment group. HFpEF 
is a condition that predominantly  affects an elderly  population. Age is also an important risk 
factor for cognitive decline and amyloid deposition. The entry  requirement of [ADDRESS_443639] of care (ACEI) to patients wit h HFrEF, these patients will be excluded from the 
study . However ,given the similarity  of the population and patient characteristics, the results 
of this study  should be relevant to the heart failure population at large regardless of ejection 
fraction.
Thestudy  aims to assess the effect of LCZ696 compared to valsartan on cognitive function in 
patients with normal cognition and mild cognitive impairment (MCI) , while excluding 
patients with significant impairment, (e.g. patients with an MMSE score of <24; Holsinger et 
al2007 ). Available data suggest that amyloid plaque deposition may reach a plateau once a 
patient is clinicall y diagnosed with AD (Bateman et al 2012 ). The rate of cognitive decline in 
AD patients is not uniform as it is dependent on various factors. Hence patients with a clinical 
diagnosis of AD or dementia will also be excluded from this study .
Further details about the patient population are provided in Section 4 .
Active run -in period:
The single -blind epoch will help ensure that only patients who are likely  to tolerate and 
maintain study  drug for the long term follow -up are randomized; this will  minimize the 
potential forearly drop out, which is critical to assess the impact of long -term therapy  of 
study  medications for up to 3 years on cognitive function. In addition, the single blind 
treatment run-in epoch mimics clinical practice (where patients are only continued on 
treatments if they  are tolerated). 
The current treatment run-in design will assess the safet y and tolerability of patients to drug 
dose level 2 (L CZ696 100 mg bid). Drug dose level 3 (L CZ696 200 mg bid) is not included in 
the run-in design as the great majorit y of patients who tolerated 100 bid were able to tolerate 
200 bid in the run -in period of the PARADIGM -HFtrial.

[COMPANY_001] Page 30
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Baseline assessments will be made at the time of randomization visit following exposure to 
both study  medications in the run-in period. In addition, brief exposure with LCZ696 during 
the run -in period is unlikely  to have an impact on baseline study  assessments. 
Primary  endpoint selection: 
The primary  endpoint of the study  is change in cognition ,which is assessed as the change in 
the Global Cognitive Composite Z scores (GCCS) from baseline (randomization) over 3 years. 
There is no absolute or clear demarcation between cognitive domains affected in Alzheimer’s 
dementia compared to vascular dement ia. However some distinctions can be made between 
the two conditions in terms of the domains that are predominantly  affected. For example, 
executive function is typi[INVESTIGATOR_356197]. In 
contrast, cognitive domains encompassing memory  functions are more often affected in 
Alzheimer’s dementia although other faculties are also affected ( Cavalieri et al 2010 ,Gorelick 
et al 2011 ,Lim et al 2012 ).  Thus a composite score of relevant domains provides a 
comprehensive assessment of cognitive function in the study  population.
The principle of using cognitive composite is well established and has been used in multiple 
studies in AD and depression (Alzheimer’s disease assessment scale -cognitive subscale 
(ADAS -Cog)
, MATRI CS cognitive assessment battery  (MCCB );Raghavan et al 2013 ,Vellas 
et al2015
,Maruff and Jaeger 2015 ). The Alzheimer’s Prevention Initiative has recommended 
the use of a composite clinical assessment as a primary  endpoint rather than selecting a single 
cogniti ve assessment or individually  examining multiple cognitive assessments (Langbaum et 
al2015 ). A similar approach has been advocated by [CONTACT_104412]’s Disease Cooperative 
Study  group ( Donohue et al 2014 ).
The specific domains of cognition to be measured include psychomotor function, visual 
attention, working memory , executive function, visual learning and verbal learning and 
memory .  These cogniti ve functions have 
been selected on the basis of their known sensitivity  
to changes in amyloid levels (Villemagne et al 2013 , Lim et al 2014 ) and cerebral vascular 
function (Collie et al 2002 ,Clark and McDougall 2006 , Steinberg et al 2015 ,) in humans.  The 
cognitive functions will be measured using a set of computerized neuropsy chological tests 
from the CogState Cognitive Battery  (CCB ) (Maruff et al 2013 , Mielke et 
al 2014 ). The tests 
from the CCB have been selected on the basis of their extensive use and demonstrated 
sensitivity  to cognitive decline associated with heart disease (Hammers et al 2013 , Arslanian -
Engoren et al 2014 ,Cannon et al 2015, Lansky  et al 2015, Chou et al 2015 ), preclinical 
Alzheimer’s disease (Darby [CONTACT_2297] 2011 , Lim et al 2013, Lim et 
al 2015 ) and cerebrovascular 
disease (Silbert et al 2004 , Steinberg et al 2015, Lansk y et al 2015 ).  Changes in performance 
on the CCB have also been shown repeatedly  in response to treatment with central nervous 
system (CNS) active drugs (Thomas et al 2008 ,Padmanabhan et al 2009 ,Kay et al 2012 ,
Grove et al 2014 ,Snyder et al 2014 )
.
The CCB has been selected as it is designed specificall y for repeated administration with 
minimal practice or learning effects and performance on the cognitive tests themselves are not 
influenced by [CONTACT_356231], cultural or educational background of participants.  Computer 
based testing allows the CCB to be administered in clinical trials by [CONTACT_356232] - expert 
clinical trials staff, which makes it ideal for use in a heart failure population ( Lim et al 2014 ).  

[COMPANY_001] Page 31
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
The three year duration was chosen for the study  as available literature suggests that clinicall y 
relevant deterioration in cognition is associated with increases in amyloid deposition and is 
demonstrable over a period of 36 months (Villemagne et al 2011 , Chen et al 2015 ). Although 
cognitive decline in the setting of AD occurs gradually , in several studies enrolling patients 
with mild cognitive impairment, patients progress to dementia at a rate of about 15% per year, 
with the majority  of patients converting to frank dementia after 3to 4 years (Belleville et al 
2014 ). 
Older adults who are cognitivel y normal but who show elevated levels of amyloid at their 
initial assessment ha
vean increased rate of progression to clinically classified MCI or 
dementia over [ADDRESS_443640] of patients are no longer on 
study  medication by 3 years (I-Preserve study ; Massie et al 2008 ). Thus the 3 year duration is 
considered to provide an appropriate time period to study  the trial objectives while retaining 
as many  evaluable patients as possible.
Secondary  endpoint selection: 
Amyloid PET imaging
Change in brain amyloid deposition assessed by [CONTACT_356233] a key secondary  endpoint. 
Two studies (Chen et al 2015 ,Landau et al 2015 ) have shown that longitudinal change in 
brain amyloid plaque load over [ADDRESS_443641] shown that high cerebral Aβ load in non- demented subjects 
was associated with greater decline in epi[INVESTIGATOR_356198] 
18 months (Lim et al 2012 ). The current study  enrolls non -demented patients regardless of 
their baseline amyloid status. Given that the expected rate of deposition of amyloid in this 
population is variable, this study  will assess amyloid PET change and cognitive function over 
a 3 year period while the majority  of patients are still likely  to be continuing on study 
medication. The study will assess the change in a composite cortical florbetapir 18F 
standardized uptake value ratio (SUVr )as a measure of am yloid plaque load.
Instrumental activities of daily  living ( IADL) as assessed by  [CONTACT_356234] A ctivity 
Questionnaire (FA Q)
Performance of activities of daily living is an important factor that significantly  impacts a 
patient’s quality  of life. Intact activities of daily living (ADL) are often used as criteria to 
distinguish MCI from dementia. FAQ provides a standardized assessment of instrumental 
ADL s with high sensitivity  to identify  functional impairment. As functional changes in 
instrumental activities of daily living (IADL) that require higher cognitive ability  are seen 
earlier in the dementia process, these will be evaluated using the Functional Activities 
Questionnaire (FAQ). This functional assessment of the patient using the FAQ will 

[COMPANY_001] Page 32
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
complement the GCCS by  [CONTACT_356235], phy sical 
health, and functional capacity  (Castilla -Rilo et al 2007 ).
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
LCZ696 dose of 200 mg twice daily  was chosen as the target dose because it delivers similar 
valsartan exposure (assessed by [CONTACT_170264] (AUC )) as Diovan®(valsartan) 160 mg 
twice daily  and is the approved target dose for patients with heart failur e. Furthermore, 
biomarker analysis and modeling indicate that the 200 mg dose of LCZ696 delivers 
approximately  90% of its maximal NEP inhibition. Twice daily  dosing schedule is considered 
necessary  for sustained NEP inhibition over a 24-hour 
period and it is anticipated to reduce 
the incidence of hypotension in HF patients, particularl y in elderl y patients. LCZ696 200 mg 
bid has been utilized in the recently  completed Phase 3 PARADIGM -HFtrial in HFrEF, and 
Phase 2 trial in HFpEF (PARAMOUNT), as well as thecurrent lyongoing Phase 3 
PARAGON -HFtrial in HFpEF. The LCZ696 200 mg b.i.d dose was well tolerated and a 
significant majorit y of patients were maintained on this dose level in the completed studies.

[COMPANY_001] Page 33
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Dosing is based on the total amount of both components of LCZ696, that is, 24 mg/26 mg, 49 
mg/51 mg, and 97 mg/103 mg as sacubitril/valsartan sodium salt complex and is referred to as 
LCZ696 50 mg, 100 mg, and 200 mg respectively .
3.4 Rationale for choice of comparator
There is no proven therapy  to date that has convincingl y been shown to reduce morbidit y and 
mortality in patients with HFpEF (Yusuf et al 2003 , Cleland et 
al 2006 , Massie et al 2008 ). 
Valsartan is being given to treat the comorbidities that are prevalent in HFpEF, such as 
hypertension (HTN )
, diabetes mellitus (DM), and coronary  artery disease where there is an 
indication for RAS blocking therapy  (McMurray et al 2012 ). Data from studies in patients 
with HFpEF suggest that background ACE ior ARBs for treating comorbidities is common 
practice, including the recent TOPCAT study  where a RAS blocker was used in 85% of 
patients at baseline (Desai et al 2011 ). Valsartan was chosen as the RAS blocker comparator 
because it is one of thecommonly  prescribed ARB s, and the target dose of LCZ696 200 mg 
delivers systemic 
exposure similar to the target dose of valsartan 160 mg. Patients in both 
groups will receive a similar amount of valsartan, which will allow careful assessment of 
neprily sin inhibition on cognitive function and the sign/sy mptoms of HF. In the PARAGON -
HFstudy  valsartan is also used as the comparator. Furthermore, a placebo comparator is not 
considered appropriate in this long term trial, as the comorbidities commonly  present in 
HFpEF patients ty pi[INVESTIGATOR_1306] y require RAS inhibition (i.e., ACE ior ARB).
3.5 Purpose and timing of interim analy ses/design adaptations
Not applicable
3.6 Risks and benefits 
LCZ696, through its unique mode of action potentiates beneficial endogenous vasoactive 
peptides via NEP inhibition while inhibiting the Renin Angiotensin System (RAS) via 
angiotensin II type 1 receptor blockade . Consistent with this mechanism of action, the 
recentl y completed landmark randomized trial (PARADIGM -HF, N=8442) demonstrated that 
LCZ696 was superior to enalapril (current standard of care) in reducing cardiovascular (CV) 
death and heart failure hospi[INVESTIGATOR_356196]. The magnitude of these 
advantages of LCZ696 over an angiotensin converting enzyme (ACE) inhibitor was 
statistically  significant and clinically  relevant, particularl y since the drug was compared with 
current standard of care with an established mortality  benefit in HF patients (McMurray  et al 
2014 ). In this study , compared with enalapril (ACEI), LCZ696 demonstrated a 20% risk 
reduction for HF hospi[INVESTIGATOR_356192] (prima ry endpoint, p =0.0000002), 20% risk 
reduction in CV death alone (p=0.[ZIP_CODE]), and 21% risk reduction in HF hospi[INVESTIGATOR_253228] 
(p=0.[ZIP_CODE]), In addition, LCZ696 also demonstrated great benefit in symptom improvement, 
total HF hospi[INVESTIGATOR_059], all cause hospi[INVESTIGATOR_356199].
The mechanism of action of LCZ696 suggests 
that it also may impact the suspected 
pathophy siology  of HFpEF. In the Phase 2PARAMOUNT study , 12 weeks of treatment with 
LCZ696 resulted in a signi ficant reduction in N-terminal pro-brain natriuretic peptide (NT-
ProBNP )and the reduction was sustained at [ADDRESS_443642] been 

[COMPANY_001] Page 34
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
associated with improved outcomes in patients with heart failure ( Masson et al 2008 ).  NYHA 
class improved significantly  and s ignificant reductions in echocardiographic parameters of left 
atrial size were seen at 36 weeks supporting the hypothesis that LCZ 696 might alter the 
pathophy siology  and natural course of disease in HFpEF. LCZ696 was well tolerated in the 
completed Phase 2 trial in patie nts with HFpEF (PARAMOUNT) and Phase 3 trial in patients 
with HFrEF (PARADIGM -HF) with a safety  profile similar to that of comparators.
Patients will be instructed not to take any RAS blockade medications (ACE i,ARB or renin 
inhibitor ) on the day they start treatment run-in study  drug to avoid excess RAS blockade. 
Concomitant ACE ior ARB will be replaced by [CONTACT_356236] (valsartan). All patients will 
continue to receive RAS therap y (valsartan or LCZ696) for the entire study  duration. All 
patients will be allowed to continue receiving the rest of their background CV medications.
The patient should be on an optimal medical regimen of diuretics and background
medications to effectively treat comorbidities, such as hypertension, diabetes mellitus, atrial 
fibrillation, and coronary artery disease.
PET scanning involves intravenous administration of radiotracers, but the exposure to 
radiation is very minimal as the dose of approximate 10 millicuries radiation is received at 
each PET scanning visit. Florbetapir 18F, similar to other radiopharmaceuticals, contributes to 
a patient’s overall long
-term cumulative radiation exposure. 
The risk to patients in this trial will be minimized by [CONTACT_356237].
Neprily sin (neutral endopeptidase or NEP) is one of several proteases capable of degrading 
Aβ. Although the relative contribution of neprily sin to Aβ clearance in humans is not 
understood, the potential exists for Aβ levels to be altered by [CONTACT_356238]. The 
clinical significance of this is unknown. Altered clearance of brain Aβ peptide has been 
suggested as a potential mechanism in the pathogen esis of Alzheimer’s disease .  Short term 
administration of LCZ696 400 mg once daily in healthy  subjects for 14 days did not result in 
changes in CSF Aβ40 and Aβ42 concentrations, despi[INVESTIGATOR_356200]657 (neprily sin inhibitor moiety  of LCZ696) in the CSF relevant for neprily sin inhibition. 
The clinical relevance o f the increase in CSF Aβ [ADDRESS_443643] of LCZ696 on AD or dementia.  
In a large retrospective study  it was observed that use of ACE inhibitors was associ ated with 
improvements in cognitive performance in patients with heart failure (Zuccala et al 2005 ). 
Similarly  data from a small randomized trial indicate that in elderl y hypertensive patients 
treatment with valsar tan may be associated with improvement in some components of 
cognitive function (Fogari et al 2004 ). Although the long-term effects of treatment with 
LCZ696 on cognitive performance remains unknown ,it is possibl e that an improvement in 
cardiovascular function as a result of treatment with LCZ696 might benefit cognition in 
patients with heart failure. 

[COMPANY_001] Page 35
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Since this is a long-term study , participating patients will benefit from careful monitoring and 
follow -up during the entire study  duration regardless of whether they are receiving the study 
medication. In addition, patients can visit their doctors at an unscheduled visit as necessary .
[ADDRESS_443644] of male and female patients (≥ 60 yearsold) with chronic 
symptomatic HF (NYHA class II-IV). Eligible patients are those with the symptoms of HF, 
LVEF > 40%. 
The goal is to randomize a total of approximately  520 patients in more than 100 centers 
worldwide. With an expected screening and run-infailure rate of approximately  40%, it is 
estimated that approximately  [ADDRESS_443645] fulfill all of the following criteria:
1.Written informed consent including consent for APOE [ADDRESS_443646] be obtained 
before an y assessment is performed.
2.Male or female patients aged ≥60 y ears of age.
3.Chronic heart failure with curren t symptom(s) (NYHA class II -IV) at S creening visit.
4.LVEF >40% 
a.By [CONTACT_356223] 6 months prior to 
screening visit .OR
b. B y an echocardiogram performed during the Screening visit, if previ ous 
assessment is not available .
5.NT-proBNP ≥ 125 pg/mL at Screening visit
6. Patient with evidence of adequate functioning (e.g.: intellectual, motor, visual and 
auditory ) to complete the study  assessments and has elementary education or 6 years 
of sustained employ ment.
4.2 Exclusion criteria
Patie nts fulfilling any of the following criteria are not eligible for inclusion in this study . No 
additional exclusions may be applied by [CONTACT_093], in order to ensure that the study 
population will be representative of all eligible patients.
1.Current a cute decompensated HF requiring augmented therapy  with diuretics, vasodilators 
and/or inotropic drugs .  If hospi[INVESTIGATOR_356201] 2 w eeks 
prior to screening .
2.Acute coronary  syndrome (including myocardial infarction ( MI)), cardiac surgery , other 
major CV surgery , or urgent percutaneous coronary  intervention (PCI ), carotid surgery  or 

[COMPANY_001] Page 36
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
carotid angioplast y, history  of stroke or transient isc hemic attack within the 3 months prior 
to Screening visit or an electi ve PCI  within 30 days prior to S creening visit.  
3.Patients with history  of hereditary  or idiopathic angioedema or angioedema related to 
previous ACEi or ARB therapi[INVESTIGATOR_014] .
4.Patients with one of the following:
a.Patients with serum po tassium >5.2 mmol/L  (mEq/L ) at S creening visit
b.Patients with serum potassium >5.4 mmol/L  (mEq/L ) at any  visit during run -in 
treatment period or at randomization visit
c.Systolic blo od pressure (SBP) ≥180 mmHg at S creen ing visit, or 
d.SBP <1 10 mmHg at S creening visit, or
e.SBP <100 mmHg or s ymptomatic hy potension as determined by  [CONTACT_356239] 103 or at randomization visit
f.Body mass index ( BMI ) >45 kg/m2
5.Patients who require treatment with 2 or more of the following: an ACE i, an ARB or a 
renin inhibitor.
6.Patients with 
a.known pericardial constriction, genetic h ypertrophic cardiom yopath y, infiltrative 
cardiom yopath y or
b.hemody namicall y significant obstructive valvular disease .
7.Life-threatening or uncontrolled dy srhythmia, including s ymptomatic or sustained 
ventricular tach ycardia and atrial fibrillation or flutter with a resting ventricular rate >110 
beats per minute .
8.Evidence of hepatic disease as determined b y any one of the following: SGOT ( aspartate
aminotransferase (AST) ) or SGPT (alanine aminotransferase (ALT )) values exceeding 3 x 
the upper limit of normal (ULN), bilirubin >1.5 mg/dl at screening visit .
9. Patients with one of the following:
a.eGFR <30 mL/min/1.73m2as calculated b y the Modification ofDiet in Renal Disease  
(MDRD) formula at Screening visit, or
b.eGFR <25 mL/min/1.73m2at Visit 103 or at end of run -in/randomization v isit, or
c.eGFR reduction >35% (compared to Visit 1) at Visit 103 or Visit 199/201
10.Presence of known functionally  significan t bilateral renal artery  stenosis
11.MMSE score <24 at screening visit 
12.Patients with a clinical diagnosis of Alzheimer’s disease or other dementia syndromes or
any indication for or current treatment with cholinesterase inhibitors and/or another 
prescription AD treatment (e.g. memantine).
13.Any history  of medical or neurological condition likely  to affect the participant’s 
cognition (e.g., clinically  significant brain trauma with loss of consciousness > 3minutes
within 6 months prior to screening , Huntington’s disease, Parkinson’s disease, Ly me’s 
disease, s yphilis, HIV dementia, uncontrolled seizure disorder )or clinically significant 
abnormal ities in thy roid function tests, Vitamin B12 or folate deficiency requiring 
treatment at screening (Patients who are adequately  treated may  be included at 
investigator discretion ).

[COMPANY_001] Page 37
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
14.Inability  to perform cognitive battery  or other study  evaluations based on significant 
motor ( e.g. hemiplegia, muscular- skeletal injury ) or sensory  (blindness, decreased or 
uncorrected visual or auditory  acuity )skill.
15.Score “y es” on item [ADDRESS_443647] 6 months, or “y es” on any  item of the Suicidal Behavior 
section, except for the “Non -Suicidal Self-Injurious Behavior” (item also included in the 
Suicidal Behavior section), if this behavior occurred in the past [ADDRESS_443648] cogn ition as assessed b y MRI central reader .
17.Any contraindication or intolerance to MRI or PET investigations (with fluorinated 
radiopharmaceuticals), including but not limited to: presence of pacemakers not 
compatible with MRI , aneury sm clips, artificial hea rt valves, ear implants, or foreign 
metal objects in the ey es, skin, or body  that would contraindicate an MRI scan; or any  
other clinical history  or examination finding that, in the judgment of the investigator, 
would pose a potential hazard in combination with MRI .
18. Previous or planned Nuclear Medicine Radiology  research that will exceed the dosimetry  
acceptable exposure in the country , when adding the scheduled stud y PET scans.
19.Any surgical or medical condition, which in the opi[INVESTIGATOR_871], ma y place the 
patient at higher risk from his/her participation in the study , or is likel y to prevent the 
patient from compl ying with the requirements of the study  or completing the study .
20.Any surgical or medical condition which might significantly  alter the absorption, 
distribution, metabolism, or excretion of study  drugs, including but not limited to history  
of pancreatic injury , pancreatitis or evidence of impaired pancreatic function/injury  within 
the last [ADDRESS_443649] 12 months
24.History  or presence of any  other disease with a life expectancy  of <[ADDRESS_443650] had 12 months of natural (spontaneous) amenorrhea with an 
appropriate clinical profile (e.g. age appropriate, history  of vasomotor sy mptoms) or have 
had surgical bilateral oophorectom y (with or without hysterectom y) or tubal ligation at 
least six weeks ago. In the case of oophore ctomy  alone, only  when the reproductive status 
of the woman has been confirmed b y follow up hormone level assessment.
26.Persons directl y involved in the execution of this protocol
27.Use of other investigational drugs at the time of enrollment, or within 30 day s, or within 5 
half-lives of enrollment, whichever is longer.
28.Patients who previously  received treatment with LCZ696.
29. Patients who are on current treatment with sedative hypnotics, selective serotonin re-
uptake inhibitors (SSRI s, e.g. paroxetine, sertralin e, citalopram, escitalopram), serotonin 

[COMPANY_001] Page 38
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
norepi[INVESTIGATOR_263857] -uptake inhibitors (SNRI s, e.g. venlafaxine, duloxetine), aty pi[INVESTIGATOR_246823], and low dose tricy clic anti -depressants should be on a stable regimen 
(defined as no change to the participant’s med ication intake pattern rather than adherence 
to the prescribed regimen) for at least 12 weeks prior to screening.
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
The sponsor will provide the following stud y drugs:
Single -blind treatment run -inperiod
All eligible patients will enter a treatment run-in epoch where they will receive valsartan 
followed b y LCZ696.
The following stud y drugs will be provided:
Valsartan 40 mg and 80 mg tablets
Placebo to match valsartan 40 mg and 80 mg tablets
LCZ696 50 and 100 mg tablets
Placebo to match LCZ696 50 mg and 100 mg tablets 
The use of an ACE i, ARB or renin inhibitor in addition to study  drug during the treatment 
run-in epoch is strictl y prohibited.
Randomized treatment period
All eligible patients will be rando mized to either LCZ696 200 mg bid(dose level 3) or 
valsartan 160 mg bid(dose level 3). In addition, patients will continue to take optimal 
background therap y to treat co-morbid conditions, as considered appropriate by [CONTACT_356240], with the exception of an ACE ior ARB as 
this will be replaced by  [CONTACT_24331]. The use of an open -label ACE i,an ARB or renin inhibitor
in addition to randomized study  drug is strictl y prohibited.
The following stud y drugs will be provided:
LCZ696 50 mg, 100 mg and 200 mg tablets
Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
Valsartan 40 mg, 80 mg and 160 mg tablets
Placebo to match valsartan 40 mg, 80 mg, 160 mg tablets
In some countries where LCZ696 is approved the 50, 100 and  200 mg doses of LCZ696 are 
referred as 24/26 mg (sacubitril/valsartan), 49/51 mg (sacubitril/valsartan) and, 97/103 mg 
(sacubitril/valsartan), respectivel y.
All study  medications will be supplied in bottles. Sufficient medication will be provide d for 
the treatment according to study  protocol, including additional medication to allow for 

[COMPANY_001] Page 39
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
delay ed visits. Medication labels will be in the local language and comply  with the legal 
requirements of the country . They  will include storage conditions for the drug and the 
medication number, but no information about the patient.
5.1.2 Additional treatment
No additional treatment bey ond investigational treatment is requested for this trial.
5.2 Treatment arms
Patients will be assigned to one of the following two treatment arms in a ratio of 1:1 at the 
randomization visit.
LCZ696 200 mg bid
Valsartan 160 mg bid
5.3 Treatment assignment and randomization 
At Visit 199, patients will be scheduled to undergo a PET scan.  PET scan images will be 
centrall y read by [CONTACT_356241] a patient as amyloid positive or amyloid 
negative. Patients will be stratified at Visit 201 according to their amyloid status within 3 to 5 
days after acquisition of the baseline PET image .The investigator will remain blinded to the 
amyloid status . Since it may  take several day s to obtain results, it is recommended that the site 
take this into consideration when scheduling Visit 201, while keepi[INVESTIGATOR_356202] s tudy 
medication.   All eligible patients will be randomized via Interactive Response Technology 
(IRT) to one of the treatment arms. The investigator or his/her delegate will contact [CONTACT_356242]/exclus ion criteria. The IRT will 
assign a randomization number to the patient, which will be used to link the patient to a 
treatment arm and will specify  a unique medication number for the first package of 
investigational treatment to be dispensed to the patient . The randomization number will not be 
communicated to the caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by [CONTACT_105240] y Management using a validated system that automates 
the random assignment of medication numbers to packs containing the investigational drug(s). 
Randomization will be stratified by [CONTACT_356243], age (<75, ≥75 years old), MMSE summary 
score at baseline (<28, ≥28), and brain amyloid status (unknown, amyloid (+) or amyloid ( -)).  
Note that patients who do not participate in the PET imaging sub-study  will be classified as 
having unknown am yloid status.
The randomization scheme for patients will be reviewed and approved by a member of the 
[COMPANY_001] Randomization Group.

[COMPANY_001] Page 40
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
5.4 Treatment blinding
Patients, investigator staff, persons performing the assessments, and data analy sts will remain 
blinded to the identity  of the treatment from the time of randomization until database lock, 
using the following methods: 
Randomization data are kept strictly  confidential until the time of unblinding, and will not 
be accessible b y anyone involved in the study with the following exceptions: 
1. The independent and unblinded statistician, programmer and data personnel who are 
involved in preparing safety  review reports for the Data Monitoring Committee 
(DMC).  These personnel will not be involved in any  other trial conduct related 
activities. 
2.The DMC members who review the interim safet y data.
The identity  of the treatments will be concealed b y the use of investigational treatment 
that are all identical in packaging, labeling, schedule of administration, appearance, taste 
and odor.
A double- dummy  design is used because the identity  of the investigational treatment 
cannot be disgui sed due to their different forms.
Unblinding will only occur in the case of patient emergencies (see Section 5.5.9 ), at the time 
of safet y and efficacy  data review by [CONTACT_356244] .An 
assessment will be done by [CONTACT_18606] (or designee) 
after treatment code break and the patient must discontinue the study  treatment.
5.[ADDRESS_443651] Number will not be reused. 
Upon signing the informed consent form (ICF), the patient is assigned the next sequential 
number by [CONTACT_093]. The investigator or his/her staff will contact [CONTACT_356245]. The site 
should select the Case Report Form (CRF) book with a matching Subject Number from the 
Electronic Data Capture (EDC) s ystem to enter data. 
If the patient fails to be treated for any reason, the IRT must be notified within 2 day s that the 
patient was not treated. The reason for not being treated will be entered on the Screening 
Disposition CRF. Patients that take treatment run-in study  drug and are not randomized are 
considered run-in failures. The reason for failure to randomize will be entered on the Run-in 
Disposition CRF.
5.5.2 Dispensing the study drug
Each stud y site will be supplied with study  drug in packaging of identical appearance.

[COMPANY_001] Page 41
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
The study  drug packaging has a 2-part label. A unique medication number is printed on each 
part of this label which corresponds to one of the two treatment arms and a dose level. 
Investigator staff will identify  the study  drug package(s) to dispense to the patient by 
[CONTACT_105245](s). Immediatel y before dispensing 
the package to the patient, investigator staff will detach the outer part of the label from the 
packaging and affix it to the source document (Drug Label Form) for that patient’s unique 
subject number.
5.5.3 Handling of study  and additional treatment 
[IP_ADDRESS] Handling of study  treatment 
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and 
designees have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels. Clinical supplies are to be dispensed only in accordance 
with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] Country 
Pharma Organization ( CPO )Quality  Assurance.
Medication labels will be in the local language and comply  with the legal requirements of 
each country . They  will include storage conditions for the study  treatment but no information 
about the patient except for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_18609]. Patients will b e asked 
to return all unused study  treatment and packaging at the end of the study  or at the time of 
discontinuation of study  treatment. 
At the conclusion of the study , and as appropriate during the course of the study , the 
investigator will return all unused study  treatment, packaging, drug labels, and a copy of the 
completed drug accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided 
in the investigator folder at each site.
[IP_ADDRESS] Handling of additional treatment 
Not applicable.
5.5.[ADDRESS_443652] until the next scheduled office 
visit. In order to adequately  blind the study , patients will be required to take a total of two 
tablets (one tablet from the LCZ696/LCZ696 matching placebo pack and one tablet from the 
valsartan/valsartan matching placebo pack) twice a day for the duration of the study . Table 5-
1summarizes the study  drug that will be taken during the run-in epoch and Table 5-
2
summarizes the study  drug that will be taken during the randomized treatment epoch.

[COMPANY_001] Page 42
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Table 5-1 Study  drug dispensed for the treatment run -in epoch by [CONTACT_356246]696 Valsartan
101a1 50 mg matching placebo bid 40 mg bid
102 2a100 mg matching placebo bid 80 mg bid
103 2a100 mg bid 80 mg matching placebo bid
a Investigators may consider initiating treatment on dose level 2 (valsartan 80 mg bid and 100 mg matching 
placebo bid ) at Visit 102 (see Figure 3 -2) in those patients being treated with at least the minimum dose of ACE i
or ARB at Visit 1 (see Table 3 -1); bid – twice daily dosing
Table 5-[ADDRESS_443653] be maintained for as long a duration as possible. If down -titration is necessary due to side 
effects, the patient should be re-challenged as soon as medically possible per the investigator’s judgment.
bOnly if dose level 3 is not tolerated despi[INVESTIGATOR_356203].
cOnly if dose levels 2 or 3 are not tolerated despi[INVESTIGATOR_356203] .
bid – twice daily dosing
Patients will be instructed to take their morning study  drug doses between 06:00 and 09:00 (6 -
9 AM) and their evening study  drug dose s between 18:00 and 21:00 (6-9 PM). The study 
drugs should be taken with water, with or without food. If the patient misses taking any study 
drug dose, he/she should take it as soon as possible, unless it is almost time for the following 
scheduled dose. In this case, the patient should skip the missed dose and return to his/her 
regular stud y drug administration schedule.
All kits of investigational treatment assigned by  [CONTACT_109027]/databased in the IRT.
The investigator should promote compliance by [CONTACT_356247] y as prescribed and by [CONTACT_356248]’s 
safet y and the validity  of the study . The patient should be instructed to contact [CONTACT_356249]/she is unable for any  reason to take the study drug as prescribed.
5.5.5 Permitted dose adjustments and interruptions of study  treatment 
For patients who are unable to tolerate the protocol -specified dosing scheme, dose level 
adjustments and interruptions of study  treatment are permitted in order to keep the patient on 
study  drug. The following guidelines should be followed:
Ever y attempt should be made to maintain patients at the target study  drug dose level 
throughout the trial. If the patient cannot tolerate the target study  drug dose level, the 
investigator should consider adjust ingor stoppi[INVESTIGATOR_356204]-morbid conditions, before considering down titrat ion to the next lower dose level of study 

[COMPANY_001] Page 43
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
drug. For hypotension or dizziness, consideration should be given to reduc ingthe dose or to 
stoppi[INVESTIGATOR_356205], or reducing the dose of diuretic.
There are three dose levels of study  medication (both LCZ696 and Valsartan) as depi[INVESTIGATOR_50392] 5-2with target dose level as ‘3’.Two other dose levels (dose level 1 and 2) are 
available for down -titrating the patient depending on the clinical need and investigator’s 
discretion.
The target dose level for this study  is LCZ696 200 mg bid and valsartan 160 mg bid (Dose 
level 3).
Adjustment of study drug dose level
If despi[INVESTIGATOR_356206], then theinvestigator may consider down titrating the study  drug dose 
level according to the following instructions:
During the randomized treatment epoch, down t itration of the study  drug at any  time based on 
the judgment of the investigator will be allowed according to the safety  and tolerabilit y 
criteria defined in Appendix 3, Appendix 4, and Appendix 5. If down titration is necessary, 
the patient should be down titrated to the next lower study  drug dose level (Table 5-2). The 
patient may  continue receiving the lower dose level for a recommended period of 1 to 4 weeks 
before being re-challenged at the next higher dose level. For example, a patient who 
encounters tolerability  problems at the dose level 3 (the target study  drug dose level), should 
receive the study  drug at dose level 2 for 1 to 4 weeks at the discretion of the investigator. 
Then, he/she should be re -challenged with up- titration back to dose level 3.
If the tolerability  issues are not alleviated despi[INVESTIGATOR_356207], the 
investigator may down titrate further to the next lower study  drug dose level for 1 to 4 weeks, 
up to temporary  discontinuation of the study  drug. Again, once stabl e, the patient should be 
re-challenged with up titration to the next higher dose level every  1 to 4 weeks in an attempt 
to bring back the patient gradually  to dose level 3 (the target study  drug dose level ). The 
investigator may choose the next dose level for down -or up-titration according to his or her 
judgment (Table 5-2). As discussed in Section 5.5.4 , the IRT system should be contact[CONTACT_18612]’s study  drug dose level, including in cases of temporary 
and permanent discontinuation of the study  drug, and to obtain the medication numbers of the 
study  drug supplies required for the new stud y drug dose level.
In some instances , according to the safet y and tolerability  criteria and the investigator’s 
judgment, dose level 1 or 2 could be maintained if he/she considers that the patient’s 
condition would not allow any further up titration to the target dose level of study  drug (dos e 
level 3). In this case, it would be acceptable to maintain the patient at dose level [ADDRESS_443654] CRF.
Study drug restart after temporary  treatment interruption
Study  drug should be reintroduced in those patients who temporarily  discontinue it as soon as 
medically  justified in the opi[INVESTIGATOR_871]. 

[COMPANY_001] Page 44
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Once the investigator considers the patient’s condition appropriate for receiving the study 
drug, the investigator should re -start the patient on the study  drug at the most appropriate dose 
level ( Table 5 -2) per his/her medical judgment. If tolerated, the patient should be up- titrated to 
a dose level every  1 to 4 weeks to the target dose level 3, as per the investigator’s judgment. 
Should the patient not tolerate the re-start study  drug dose level, he/she may be down -titrated 
again (if appropriate) or temporarily  discontinue the study  medication again and a new 
attempt to up-titrate or reintroduce the study  drug could be considered by [CONTACT_356250] y justified in his/her judgment.
The use of an open -label ACE i, ARB or a renin inhibitor is strongly  discouraged while patient 
is off study  drug. However, if for any reason a patient off study  drug has started open -label
treatment with an ACE iit must be discontinued ≥[ADDRESS_443655] be discontinued prior 
to re-initiation of study  drug ( Table 5 -3).
These changes must be recorded on the Dosage Administration Record CRF.
In case of pregnancy  discovered during the screening or run-in epochs or during double -blind 
epochs , the patient will be withdrawn from the study  immediatel y. 
See Section 7.7 for further details on pregnan cies and reporting guidelines.
5.5.6 Rescue medication
Guidance on handling hyperkalemia, hypotension, and renal dysfunction will be provided to 
investigators (Appendix 3, Appendix 4,and Appendix 5respectively). Patients may receive 
open -label ACE is, ARBs or a renin inhibitor during the study  ONLY if the study  drug has 
been temporaril y or permanently  discontinued. I f for any reason a patient off study  drug has 
started open -label treatment with an ACEi it must be discontinued ≥[ADDRESS_443656] be recorded on the Concomitant medications/Significant non-
drug therapi[INVESTIGATOR_50061].
5.5.[ADDRESS_443657] the patient to notify the study  site about any new medications 
he/she takes after the patient was enrolled into the study . All medications, procedures and 
significant non-drug therapie s (including physical therapy  and blood transfusions) 
administered after the patient is enrolled into the study  must be recorded in the concomitant 
medications / significant non-drug therapi[INVESTIGATOR_14932].
Each concomitant drug must be individually  assessed again st all exclusion criteria/prohibited 
medication. If in doubt the investigator should contact [CONTACT_18614] a patient or allowing a new medication to be started.
Drugs known to affect cognition:
Initiation of cholinesterase inhibitor sor other prescription , AD treatment s, anti-depressant or 
psychotropic medication should be documented in the concomitant medication page. The 

[COMPANY_001] Page 45
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
relevant follow up questionnaire CRF page should be completed providing detail of the 
indication for i nitiation of such therapi[INVESTIGATOR_356208] .
Sedative hypnotics may be allowed ifparticipants are currently  on a stable regimen (defined 
as no change to the participant’s medication intake pattern rather than adherence to the
prescribed regimen) for at least [ADDRESS_443658] be withheld for 72 hours unless maintain ed on a stable regimen for 6 weeks prior to 
scheduled cognitive assessment.  
Selective serotonin re-uptake inhibito rs (SSRIs, e.g. paroxetine, sertraline, citalopram, 
escitalopram), serotonin norepi[INVESTIGATOR_263857]-uptake inhibitors (SNRI s, e.g. venlafaxine, 
duloxetine), atypi[INVESTIGATOR_34922] , and low dose tricyclic antidepressants are allowed 
provided participants are currentl y treated with a stable regimen for at least [ADDRESS_443659] 
(MRA) and any other medications known to raise potassium levels should be used with 
caution while the patient is receiving the study  drug due to the increased possibility  of 
occurrence of hyperkalemia. The investigator is encouraged to assess patients’ potassium 
levels regularl y, especially in th ose who are receiving these medications.
Phosphodiesterase -5 (PDE -5) inhibitors
PDE-5 inhibitors should be used with caution while the patient is receiving study  medication 
due to the increased possibility  of the occurrence of hy potension.
Nesiritide and i ntravenous (IV) nitrates
The concomitant administration of LCZ696 with nesiritide and IV nitrates has not been 
studied. In the event a study  patient requires the concomitant administration of nesiritide 
and/or IV nitrates with the study  medications, the in vestigator should consider starting them at 
a lower dose or slower infusion rate while monitoring the patient’s BP carefully .
HMG -CoA reductase inhibitors
Caution is recommended when co -administering LCZ696 with statins because of the potential
to raise pl asma statin levels .
5.5.[ADDRESS_443660] be stopped for ≥[ADDRESS_443661] be stopped prior to re -

[COMPANY_001] Page 46
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Medication Action to be taken
initiation of study drug
Any Renin inhibitor Discontinue study drug. The open label renin inhibitor must be stopped prior to 
re-initiation of study  drug
ACEi –angiotensin converting enzyme inhibitor; ARB –angiotensin receptor blocker
ACEis, ARBs and renin inhibitors
The concomitant use of open -label ACE is, ARBs or a renin inhibitor is strictly  prohibited 
while the patient is receiving study  drug. If there is a strong need for open label use ofACEi , 
ARB or renin inhibitor, then study  drug must be temporaril y discontinued. If the patient is to 
be started on open -label ACE i, the study  drug must be stopped for ≥[ADDRESS_443662] often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  treatment code breaks are performed using the IRT. When the 
investigator contacts the system to break a treatment code for a patient, he/she must provide 
the requested patient identify ing information and confirm the necessity  to break the treatment 
code for the patient. The investigator will then receive details of the investigational drug 
treatment for the specified patient and a fax or email confirming this information. The system 
will automatically  inform the [COMPANY_001] monitor for the site and the Study Team that the code 
has been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investigator 
will provide:
protocol number
study  drug name (if available)
patient number
In addition, oral and written information to the subject must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency , or when he/she is unavailable, to ensure that un -
blinding can be performed at an y time. 
An assessment will be done by [CONTACT_18606] (or 
designee) after an emergency  treatment code break and the patient must discontinue the study 
treatment.

[COMPANY_001] Page 47
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
5.[ADDRESS_443663] -study treatment 
At the end of the study , all patients will return for the final end of study  (EOS) visit (Visit 299) 
and be asked to return the remaining study  drug. The study  will be completed once all 
assessment up to the last participant reaches Month 36 (Visit 299) ora recommendation is 
made b y the DMC to prematurely stop the stud y. 
The study  will be complete when the last patient enrolled has completed their last visit.
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care.
A patient will be considered to have completed the study  when the patient has completed the 
last visit planned in the protocol.
5.6.[ADDRESS_443664] discontinue study  treatment for a given patient if he/she believes that 
continuation would negatively  impact the risk/benefit of trial participation.
Study  treatment must be discontinued under the following circumstances:  
Patient wish
Pregnancy  (see Section 6.5.9 and Section 7.7 )
Use of prohibited treatment as per recommendation in Table 5 -3
Any situation in which study  participation might result in a safet y risk to the patient
However; study  treatment discontinuation does not constitute withdrawal from the study  and 
should not lead to the patient being withdrawn from the study . 
Every  effort should be made to complete end of treatment (EOT) assessment s within [ADDRESS_443665] discontinued study  drugpermanently . For 
patients who terminate the study  early, they  are expected , and should be encouraged ,to attend 
all the protocol specified study  visits and perform all measurements as stipulated in the visit 
schedule (Table 6 -1) and remain in follow up for the duration of the trial. 
If they fail to return for these assessments for unknown reasons, every  effort shou ld be made 
to contact [CONTACT_476]. If the patient cannot or is unwilling to attend any  visit(s), the site staff should 
maintain regular telephone contact [CONTACT_10970], or with a person pre-designated by [CONTACT_4677]. This telephone contact [CONTACT_37283] y bedone according to the study  visit schedule.
The investigator must contact [CONTACT_105253]’s discontinuation from study  
treatment and must determine the primary  reason for the patient’s premature discontinuation 
of study  treatment and recor d this information on the Dosage Administration eCRF.
The emergence of the following circumstances will require permanent study  drug 
discontinuation:

[COMPANY_001] Page 48
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Withdrawal of informed consent
Investigator thinks that continuation would be detrimental to the patient’s well-being
Suspected occurrence of angioedema. A patient with any  signs or s ymptoms of clinically  
significant angioedema should be thoroughl y evaluated b y the investigator
Use of an open label ACE i, ARB or renin inhibitor will require temporary  or permane nt 
discontinuation (study  drug may  be restarted once these medications are stopped).
Study  drug may  be discontinued at the investigator’s discretion if an y of the following occurs:
Any severe suspected drug -related AE
Any other protocol deviation that resu lts in a significant risk to the patient’s safet y.
The appropriate personnel from the site and [COMPANY_001] will assess whether study  drug should be 
permanentl y discontinued for any  patient whose treatment code has been broken inadvertently 
for an y reason.
If study  drug discontinuation occurs because treatment code has been broken, please refer to
Section 5.5.9 .
The details about study  assessment to be completed for patient swho permanently 
discontinued study  drug are provided in Section 6 .
5.6.3 Withdrawal of informed consent
Patients/subjects may voluntarily  withdraw consent to participate in the study  for any reason 
at an y time. Withdrawal of consent from the stud y is defined as when a patient:
Does not want to participate in the study  anymore
and
Does not want an y further visits or assessments
and
Does not want an y further study related contacts
and
Does not allow anal ysis of alr eady  obtained biologic material
In this situation, the investigator must make every  effort (e.g. telephone, e -mail, letter) to 
determine the primary  reason for the patient’s decision to withdraw his/her consent and record 
this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_18618] -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient’s study  withdra wal should be made as detailed in 
Table 6 -1.

[COMPANY_001] Page 49
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
5.6.4 Loss to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
[CONTACT_762], e.g. dates of 
telephone calls, registered letters, etc. A patient cannot be considered as lost to follow -up until 
the time point of his/h er scheduled end of study visit has passed.
5.6.5 Early  study termination by  [CONTACT_356251] r any  reason. This may  include reasons 
related to the benefit -risk assessment of participating in the study , practical reasons, or for 
regulatory  or medical reasons (including slow enrolment). Should this be necessary , the 
patient must be seen as soon as possible and treated as a prematurel y withdrawn patient. The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient’s interests. The investigator 
will be responsible for informing the Institutional Review Board/Independent Ethics 
Committee (I RBs/IECs) of the early  termina tion of the trial.
6 Visit schedule and assessments
Table 6 -1lists all of the assessments and indicates with an “x” when the visits are performed. 
Patients/subjects must be seen for all visits on the designated day, or as close to it as possible. 
Missed or rescheduled visits should not lead to automatic discontinuation. 
After randomization, study  drug discontinuation (permanent or temporary ) for anyreason 
does not constitute withdrawal from the study and should not lead to the patient being 
withdrawn from the study . Patients who discontinue study  drug should be requested to return 
for an End of Treatment visit (EOT) in which all of the assessments outlined in Table 6-1will 
be performed .
Patients who prematurely  discontinue the study  for any reason should be scheduled for a visit 
as soon as possible, at which time all of the assessments listed for theend of study visit will 
be performed. At the end of study  visit, all dispensed investigational product should be 
reconciled and the adverse event and concomitant medications reconciled on the CRF.
Every  effort should be made to complete end of treatme nt (EOT) assessments within [ADDRESS_443666] discontinued study drug permanently . 
Patients who terminate study  drug early are expected, and should be encouraged to, attend all 
the remaining protocol specified study visits and perform all measurements as stipulated in 
the visit schedule (Table 6 -1). 
For EOT / End of Study  (EOS) visit, the PET and MRI scanswill only be performed if prior 
scans were performed more than twelve months ago.The CCB,  FAQ,  
assessments will only be performed if prior assessments were performed more than three 
months ago .
Documentation of attempts to contact [CONTACT_356252].

[COMPANY_001] Page 51
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Table 6-1 Assessment schedule
Epoch Screen
ingActive Run -in Randomized Treatment
Visit 1 101 102 103 199/ 
201††202 [PHONE_7400] 2061207 2081209 2101, 
2121211 EOT3UNS 2997
End 
of 
Study
Week (w) -11/-7 -8/ -4 -6/ -3 -4/ -2 0 13 26 39 52 65 78 91 104 117,
143130 156
Month 3 6 9 12 15 18 21 24 27, 33 30 36
Informed consent DS X
Inclusion/Exclusion criteria DS X X X X X
Safety monitoring criteria DS X X8X X
Demography/Relevant 
Medical history/Current 
medical conditionsDS X
Heart Failure / Smoking 
history/Alcohol history DS X
Echocardiography4DS X
Concomitant medications DS X X X X X X X X X X X X X X X X X X
NYHA classification 
(HF signs/symptoms)DS X X X X X X X X X X
Florbetapir 18F PET scan DS XλX X5X5
MRI Scan15DS X X X5X5
Cognitive Assessment 
(CogState Battery)6,12DS X X XλX X X X X X X

[COMPANY_001] Page 52
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Epoch Screen
ingActive Run -in Randomized Treatment
Visit 1 101 102 103 199/ 
201††202 [PHONE_7400] 2061207 2081209 2101, 
2121211 EOT3UNS 2997
End 
of 
Study
Week (w) -11/-7 -8/ -4 -6/ -3 -4/ -2 0 13 26 39 52 65 78 91 104 117,
143130 156
Month 3 6 9 12 15 18 21 24 27, 33 30 36
Functional Activity 
Questionnaire (FAQ)6DS X XλX X X X X X X
Physical Exam9S X X X X X X X X X X X X
Height DS X
Weight DS X X X X X X X X X X
Abbreviated laboratory 
evaluations10DS X8X X X X X X
Local laboratory11(X) (X) (X) (X)
Vitamin B12 and Folate S X
Thyroid stimulating hormone S X
FSH2S X
APOE4 genotypi[INVESTIGATOR_007] /
13DS X
NT-proBNP14DS X
Dispense study medication S X X X XλX X X X X X (X)
Contact [CONTACT_54537] S X X X X X X X X X X X X X X X X X X
Drug Accountability DS X X X X X X X X X X (X) X
Plasma -amyloid16 DS X XλX X X X X

[COMPANY_001] Page 53
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Epoch Screen
ingActive Run -in Randomized Treatment
Visit 1 101 102 103 199/ 
201††202 [PHONE_7400] 2061207 2081209 2101, 
2121211 EOT3UNS 2997
End 
of 
Study
Week (w) -11/-7 -8/ -4 -6/ -3 -4/ -2 0 13 26 39 52 65 78 91 104 117,
143130 156
Month 3 6 9 12 15 18 21 24 27, 33 30 36
Screening disposition DS X
Run-in disposition DS X
Treatment disposition DS X X
DS= assessment to be recorded in clinical database ; S= assessment to be recorded on source document ; UNS = unscheduled visit ;
EOT=(end of treatment); Patients will be contact[CONTACT_356253] [ADDRESS_443667] administration of study treatment
(X) = optional assessment
††= Visit 199/201 (end of treatment run-in) will be completed for all patients who enter the treatment run -in epoch. For patients who discontinue during the 
treatment run -in epoch, Visit [ADDRESS_443668] completed a PET scan and are randomized atVisit 201, procedures 
marked as ‘λ’ will be performed.
1Telephone visit
[ADDRESS_443669] dose.
4Qualifying LVEF measurements/documentation will be based on locally obtained most recent assessments performed ≤ 6 months prior to Visit 1. If an EF 
assessment performed ≤ [ADDRESS_443670] be performed during the Screening epoch.
5The PET and MRI scans will be done at EOT /EOS only if prior scans were performed more than twelve months ago.
6The CCB,  FAQ,  will be done at EOT /EOS only if prior assessments were performed more than three months ago
7Visit 299 (end of study visit) will be completed for all patients that enter the randomized treatment epoch.
8Serum potassium and eGFR to be performed at Visit 102 only if patient enters the run-in epoch at Visit 101.
9Complete physical exam will be per formed at Screening Visit 1, EOS, and EOT, all other visits will be a short physical exam.
10Abbreviated laboratory assessment sincludes: serum creatinine, potassium and eGFR
11Serum potassium and serum creatinine for eGFR. If patient enters run -in period at Visit 102, laboratory evaluation at this visit is not required
12Cognitive assessments should ideally be administered by [CONTACT_356254] a quiet environment and prior to any other clini cal assessments scheduled 
during the day
13If the PGsample is not collected at Visit 201 , it may be obtained at any visit thereafter and is only analyzed in patients consenting to the PG analysis
14NT-proBNP will be analyzed in serum and collected as part of the clinical chemistry sample
15MRI scans at V isit 207 and Visit 299 are performed only inpatients participating in the PET substudy
16Plasma β -amyloid will be assessed only in patients participating in the PET substudy

[COMPANY_001] Page 56
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
5.International Shoppi[INVESTIGATOR_220037] (I SLT) is a verbal list learning paradigm shown to assess 
verbal learning. 
6.The Internatio nal Shoppi[INVESTIGATOR_356209] (I SLT-DR) is a delay ed recall 
condition from a verbal list learning paradigm shown to assess verbal memory .
7.The Groton Maze Learning Test (GMLT) is a hidden pathway  maze learning paradigm 
shown to assess executive func tion.
The individual cognitive functions measured by [CONTACT_356255]; 
1.Attention: defined by  [CONTACT_356256], and Identification tests 
2.Epi[INVESTIGATOR_17120] :defined by  [CONTACT_92100] o n the CPAL ,ISLT and ,ISLT-DR
3. Executive function: defined by  [CONTACT_356257] T and ONB test   
Performance across these three domains can then be organized to provide a measure of 
general cognitive function.
These individual cognitive functions and their related cognitive domains have been selected 
for the current study  on the basis that they have been shown to be relevant to characterizing 
the cognitive impairment that can occur in patients with heart failure and underl ying CV
disease (Bauer et al 2011 ). They  also have been shown to be associated with both absolute 
levels of amyloid and rates of changes in amyloid deposition in 
older adults (Lim et al 2012 ). 
The cognitive test battery  evaluates the most relevant cognitive domains associated with 
changes in brain Aβ and changes as a result of progressive CV disease.
The cognitive tests that will be utilized in this study  exhibit appropriate sensitivity  to detect 
changes that would occur in the early , prodromal stage of AD, especiall y in patients positive 
for am yloid(Lim et al 2014 ).
Each of the cognitive tests in the CCB will be administered electronicall y to patients using a 
computer or tablet in an area suitable for testing without distraction . While subjects 
themselves perform the tests on the computer or tablet , this performance is guided by [CONTACT_160440] y trained and credentialed rater. The electronic administration ensures standard 
administration of tests and also means that the CCB can be administered with high fidelity  by 
[CONTACT_105]-expert but appropriately  trained clinical staff (e.g., research assistants or nurses).  
Assessment with the CCB should take place in a locati on free from distraction and all site 
staff nominated to administer the CCB will undergo specific training to ensure that they 
understand the testing software, the testing processes, the administration of each test and the 
transfer oftest results to CogSt ate. Further details about CogState battery  will be provided in 
CCB manual .
The cognitive test battery  will be administered at Screening visit (Visit 1), Visit 103, and 
randomization visit (Visit 201), and throughout the duration of the study  at 6 month intervals, 
including the end of treatment visit (if prior assessments were performed more than three 
months ago) and end of study  visit (Visit 
299).

[COMPANY_001] Page 57
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
6.4.2 Individual cognitive d omains
Change from baseline in individual cognitive domains (memory , executive function, and 
attention) as assessed by [CONTACT_356258] z-scores by [CONTACT_356259] 3 years will be evaluated.  
6.4.4 Instrumental activities of daily  living as assessed by  [CONTACT_356260] a standardized assessment of activities 
of daily  living. This questionnaire is typi[INVESTIGATOR_1306] y used to distinguish normal subjects from 
subjects with mild to moderate cognitive impairment. FAQ evaluation will be performed at 
Screening visit (Visit 1), randomizatio n visit (Visit 201), at 6 months (Visit 203), 12 months 
(Visit 205), 18 months (Visit 207), 24 months (Visit 209), 30 months (Visit 211), end of 
treatment visit (if prior assessments were performed more than three months ago), and at 36 
months end of study (Visit 299). The changes from baseline to 3 y ears will be anal yzed.
6.4.5 Appropriateness of efficacy  assessments 
[IP_ADDRESS] Cognitive function assessment 
The comprehensive battery  of cognitive tests has been selected as the primary  endpoint for 
this study  as it will pr ovide a measure of general cognitive function based on the performance 
in working memory , executive function, psychomotor speed, visual attention, visual epi[INVESTIGATOR_6368] , verbal learning and delay ed verbal recall. 
The CogState Cognitive Battery  (CCB) will be used to measure these cognitive domains 
because the performance measures from tests of these cognitive functions have been validated 
extensively , including in older patients with heart failure (Clark and McDougall 2006) , 
healthy  older individuals 
with increased levels of amyloid (Lim et al 2014) and in older 
patients with mild cognitive impairment and clinically  classified dementia (Maruff et 
al 2013) .  
Each test in the CCB has also been designed specificall y for the repeated administration 
necessary  in clinical trials in that they are brief to administer, reliable and that once they are 
learned, repea ted administration is not associated with performance improvement, even over 
relativel y short retest 
intervals (e.g. 1-hour) (Maruff et al 2013 , Mielke et al 2014 ).  This 
validity , brevit y and repeatability  has meant the performance on the Cog State tests is sensitive 

[COMPANY_001] Page 58
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
to true cognitive change (improvement or decline) in response to disease progression or 
treatment with pharmaceutical or surgical intervention in various disorders, diseases and 
injuries. 
When considered together the measurement of cognitive function using the CCB enables 
optimal evaluation of any cognitive decline or cognitive improvement associated with 
LCZ696 treatment.
[IP_ADDRESS] Individual cognitive domains
In additio n to an overall cognitive function assessment using the GCCS, the three main 
cognitive domains comprising the GCCS, attention, memory , and executive function, will be 
further anal yzedindependently .  
These individual cognitive functions and their related cognitive domains have been selected 
for the current study  on the basis that they have been shown to be relevant to characterizing 
the cognitive impairment that can occur in patients with heart failure and underl ying CV 
disease (Bauer et 
al 2011 ). They  also have been shown to be associated with both absolute 
levels of amyloid and rates of changes in amyloid deposition in older adults (Lim et 
al 2012). 
The cognitive tests that will be utilized in this study  exhibit appropriate sensitivity  to detect 
changes that would occur in the early , prodromal stage of AD, especiall y in patients positive 
for amyloid ( Lim et al 2014 ).  The cognitive test battery  evaluates the most relevant cognitive 
domains associated with changes in brain Aβ and changes that may occur as a result of 
progressive CV disease.
[IP_ADDRESS] Instrumental activities of daily  living as assessed by  [CONTACT_356261] (FAQ) will be used as a standardized assessment of 
instrumental 
activities of daily  living (IADL; Pfeffer et al 1982, Teng et al 2010 ). This 
questionnaire is typi[INVESTIGATOR_356210]. The test is made up of [ADDRESS_443671]’s 
ability  to perform activities of daily  living and to function independentl y. Test scores range 
for [ADDRESS_443672] and will provide an 
assessment of patient ’s phy sical and social functioning.

[COMPANY_001] Page 61
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
extremities, vascular and neurological. If indicated based on medical history  and/or sy mptoms, 
rectal, external genitalia, breast, and pelvic exams will be performed.
A short physical exam will include the examination of general appearance  
. A short phy sical exam will be conducted at all visits starting from 
Visit 102 except where a complete ph ysical examination is required (see Table 6 -1). 
Information from all physical examinations must be included in the source documentation at 
the study  site. Significant findings that are present prior to signing informed consent must be 
includ ed in the Medical History  part of the CRF. Significant findings made after signing the 
informed 
consent which meet the definition of an AE must be recorded on the AE section of 
the CRF.
6.5.7 Height and weight 
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured.

[COMPANY_001] Page 62
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320

[COMPANY_001] Page 63
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
[IP_ADDRESS] Plasma beta- amyloid
Plasma β-amyloid will be assessed in patients in the PET substudy  from select centers. Blood 
sample for plasma β-amyloid will be taken at Visit 1 (screening), 199/201 (randomization), 
Visit 202 (Week 13), Visit 205 (Week 52), Visit 209 (Week 104), end of treatment (EOT), 
and Visit 299 (Week 156).
[IP_ADDRESS] eGFR
Estimated eGFR will be calculated by [CONTACT_356262]   ( Stevens et al 2006): 
Estimated GFR (mL /min/1.73 m2) = 175 × (standardized SCr in mg/dL )-1.154× (age in years)
-0.203 × (0.742 if female) or× (1.212 if black), where SCr is the standardized serum creatinine 
value.
[IP_ADDRESS] APOE4 genotypi[INVESTIGATOR_356211]4 gene has been identified as a genetic marker that predicts predisposition to 
cognitive decline and Alzheimer’s disease (Corder et al 1993 ). To control for this 
predisposing factor, patients will be asked to provide blood samples for genotypi[INVESTIGATOR_356212]4 genot ype so that genetic predisposition is taken into 
account when assessing the cognitive functio n of the study  participants. APO E4 genot ypi[INVESTIGATOR_356213] 199/201 in all patients. The site s will remain blinded to the APO E4 status 
during the stud y.
[IP_ADDRESS] Other lab assessments
Other laboratory  tests that will be performed at Visit 1 are:
NT-proBNP
NT-proBNP will be performed by  [CONTACT_356263] 1.
Thyroid stimulating hormone ( TSH )
Vitamin B12 and Folate
Follicle stimulating hormone ( FSH)
FSH levels will be measured to confirm menopausal status in patients who have 
undergone oophorect omy without hysterectomy .
6.5.9 Pregnancy  and assessments of fertility  
Women of child bearing potential defined as all women physiologicall y capable of becoming 
pregnant are excluded. FSH levels , determined only in women who underwent oophorectom y
without hysterectomy at Screening visit (Visit 1),should be in a range consistent with 
menopausal status for the patient to continue into the run -in period .

[COMPANY_001] Page 64
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
6.5.[ADDRESS_443673] changes in amyloid plaque load over a 2 
year observation period in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Chen et 
al 2015, Landau et al 2015 ). Thesedata demonstrate that relevant changes in amyloid plaque 
deposition can be detected at 2 years using amyloid PET imaging (Villemagne et al 2011, 
Landau et 
al 2015) and that utilization of a cerebral white matter reference region may 
improve the power  to track longitudinal changes in florbetapir 18F
(Chen et al 2015).
6.6 Other assessments

[COMPANY_001] Page 65
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
6.6.2 Resource utilization
Not applicable 
6.6.3 Pharmacokinetics
Not applicable

[COMPANY_001] Page 66
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
7 Safety  monitoring
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informe d consent for participation in the 
study until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical event has occurred.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
at each visit during the study . Adverse events also may  be detected when they are volunteered 
by [CONTACT_24479], laboratory  tests, or 
other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the follow ing criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_18532]. Investigators have the responsibility  for managing the safet y of individual 
patie nt
sand identify ing adverse events. Alert ranges for labs and other test abnormalities are 
included in Appendix [ADDRESS_443674] contributed to the outcome . An individual abnormal value on a cognitive scale by [CONTACT_356264]. The investigator should 
make appropriate decision sas to the need for further neurops ychological assessments at any 
time during the study  based on clinical assessment irrespective of the cognitive scores. Results 

[COMPANY_001] Page 67
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
of SUVr assessments on amyloid PET imaging and MRI  volumetric assessments will not be 
communicated to the investigators. Patients who receive a diagnosis of MCI , dementia or 
stroke during the course of study  may  continue in the study .
Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  [CONTACT_6644].
The severit y grade 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
its relationship to the study  treatment, 
“No Relationship to study  treatment or other investigatio nal treatment ”or
“Relationship to study  treatment ”or
“Relationship to other investigational treatment ”or 
“Relationship to both study  treatment and other investigational treatment or 
indistinguishable ”
itsduration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
whether it constitutes a serious adverse event (SAE -
see Section 7.2 for definition of SAE) 
and which seriousness criteria have been met.
action taken regarding study  treatment 
All adverse events must be treated appropriately . Treatment may include one or more of the 
following: 
no action taken (i.e. further observation only ) 
study  treatment dosage increased/reduced
study  treatment interrupted/withdrawn
concomitant medication or non- drug therap y given 
patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533] (see Section 7.2 for defi nition 
of SAE)
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it must be followed until its resolution or until it is judged 
to be p ermanent, and assessment must be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  drug, the interventions 
required to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the patient 
informed consent and should be discussed with the patient during the study  as needed.  Any 
new information regardi ng the safet y profile of the medicinal product that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 

[COMPANY_001] Page 68
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Notification (IN) or an Aggregate Safet y Finding. New information might require an update to 
the informed consent and has then to be discussed with the patient.
The investigator must also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient, or the patient’s personal physician, believes 
might reasonabl y be related to study  treatment. This information should be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to [COMPANY_001].
7.2 Serious adverse events 
7.2.1 Definition of SA E 
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing )]
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the 
following criteria:
is fatal or life -threatening 
results in persistent or significant disabili ty/incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event n ot fulfilling an y of the 
definitions of an SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of anSAE refers to a reaction in which the patient was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically  might 
have caused death if it were more severe (see Annex I V, ICH -E12D Guideline ).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_105195]. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_50069] (see Annex IV, ICH -E12D Guideline ).

[COMPANY_001] Page 69
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse rea ction.
7.2.[ADDRESS_443675] be reported separatel y as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applic able sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess the relationship of each SAE to each specific 
component of study  treatment, (if study  treatment consists of several components) complete 
the SAE Report Form in English, and submit the completed form within [ADDRESS_443676] be reported as a follow -up 
to that event regardless of when it occurs.  The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Broc hure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Drug Safet y and 
Epi[INVESTIGATOR_277313]. [COMPANY_001] may need to issue an Investigator 
Notification to inform all investigators involved in any study with the same study  treatment 
that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) 
will be collected and reported to the competent authorities and relevant ethics committees in 
accordance with EU Guidance 2011/C 172/01 or as per national regulatory  requirements in 
participating countries.
7.3 Liver safet y monitoring 
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. L iver events are divided into two categories:
Liver events of sp ecial interest which consist of liver function test ( LFT)elevations

[COMPANY_001] Page 70
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Medically  significant liver events which are considered as SAEs and which consist of 
marked elevations of LFTs and / or pre -specified AEs.
Please refer to Table 14 -1in Appendix 2 for complete definitions of liver events.
Any liver event which meets the criteria for “medically  significant” event as outlined in Table 
14-1of Appendix 2should follow the standard procedures for SAE reporting as described in 
Section 7.2.
Every  liver event as defined in Table 14-1 of Appendix 2should be followed up by [CONTACT_356265]. Detailed 
information is outlined i n Table 14
-2in Appendix 2 .
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug if appropriate
Hospi[INVESTIGATOR_18539]
A causalit y assessment of the liver event via exclusion of alternative causes (e.g., 
disease, co -medications)
An investigation of the liver event which needs to be followed until resolution.
These investigation
s can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded on appropriate CRF pages, including the liver 
event overview CRF pages.
7.4 Renal safety  monitoring 
Details of monitoring and management of renal dysfunction are provided in Appendix 5 .
7.5 Cognition safety monitoring
If dementia or dementia -related event occurs, the investigator will complete a Dementia -
related Event form (provided by [CONTACT_5343]) in addition to the standard AE reporting. If a 
dementia or dementia -related event satisfies the definition of an SAE, the investigator must 
submit an SAE report in additi on to the Questionnaire for the Dementia -related Event.   
Submission of a dementia report is not a substitution for the submission of an SAE report.
7.6 Reporting of study  treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA (European M edicines Agency ) definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  [CONTACT_50104].
Study  treatmen t errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 

[COMPANY_001] Page 71
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safety  database irrespective of it being associated with an 
AE/SAE (Table 7-1 ).
Table 7-1 Guidance for capturing the study  treatment errors including 
misuse/abuse 
Treatment error 
typeDocument in Dose 
Administration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes Yes, even if not associated 
with a SAE
AE –adverse event; eCRF –electronic case report form; SAE – serious adverse event
7.[ADDRESS_443677] be 
reported to[COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalit ies, or 
maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and reported by [CONTACT_50105] y and Epi[INVESTIGATOR_18540]. Pregnancy 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study  treatment. 
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.

[COMPANY_001] Page 72
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
8 Data revie w and database management 
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and CRFs with the investigators and their staff. During 
the study , [COMPANY_001] employ s several methods of ensuring protocol and Good Clinical Practice 
(GCP )compliance and the quality /integrity  of the sites’ data. The field monitor will visit the 
site to check the completeness of patient records, the accuracy  of entries on the (e)CRFs, the 
adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to 
ensure that study  treatment is being stored, dispensed, and accounted for according to 
specifications. Key study personnel must be available to assist the field monitor during these 
visits.  Continuous remote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] CRA (clinical research associa te)organization. Additionally , a central analytics 
organization may analyze data andidentify  risks andtrends for site operational parameters, 
and provide reports to [COMPANY_001] Clinical Teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_102] (a signed copy  is given to the patient).
The investigator must give the moni tor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAE s, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -
specific monitoring plan. No information in source documents about the identity  of the 
patients/subjects will be disclosed.

[COMPANY_001] Page 73
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
8.[ADDRESS_443678] Research Organization (CRO) working on behalf of [COMPANY_001] 
review the data entered into the CRFs by [CONTACT_356266] y 
and instruct the site personnel to make any required corrections or additions. Queries are sent 
to the investigational site using an electronic data query . Designated investigator site staff is 
required to respond to the query and confirm or correct the data. If the electronic query  system 
is not used, a paper Data Query  Form will be faxed to the site. Site personnel will complete 
and sign the faxed copy  and fax it back to [COMPANY_001] staff that will make the correction to the 
database. The signed copy of the Data Query  Form is kept at the investigator site .
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Concomitant procedures, non-drug therapi[INVESTIGATOR_121899] (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
[COMPANY_001] (or a designated CRO).
Randomization codes and data about all study  drug(s) dispen
sed to the patient and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). The system will be 
supplied by a  v endor, who will also manage the database. The database will be sent 
electronically  to [COMPANY_001] (or a designated CRO) .
CogState will provide cognitive battery  data; imaging vendor will provide MRI  and PET data . 
A selected vendor will provide FAQ, data electronically to [COMPANY_001]. 
Each of these vendors will manage the database and these data will be gener ated 
electronically  using a computer or tablet. 
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  
The code break functionality  will remain available until study  shut down or upon request of 
[COMPANY_001]. 
The occurren ce of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis.Any 
changes to the database after that time can only be made after written agreement by [CONTACT_18660].

[COMPANY_001] Page 75
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
9.1 Analysis sets 
The following anal ysis sets will be used for the statistical anal yses:
Screened set (SCR) – All patients who signed the informed consent. The screened set 
includes only  unique screened patients, i.e., in the case of re- screened patients only  the 
chronologicall y last screening data is counted. 
Enrolled set (ENR) (run-in phase) –All patients who received at least one dose of run -in 
study  drug. 
Valsartan run -in set (VRS) –All patients who are in the ENR and received at least one 
dose of run- in valsartan.
LCZ696 run -in set (LRS) – All patients who are in the ENR and received at least one 
dose of run- in LCZ696.
Randomized set (RAN) –All patie nts who received a randomization number, regardless 
of receiving trial medication.
Full analysis set (FAS) – it consists of all randomized patients with the exception of those 
patients who have not been qualified for randomization and have not received st udy drug, 
but have been inadvertently  randomized into the study . Following the intent -to-treat 
principle, patients will be anal yzed according to the treatment to which they were assigned 
at randomization. 
Safety set (SAF) –it consists of all randomized patients who received at least one dose of 
study  drug. Patients will be anal yzed according to the treatment actually  received. The 
safet y population will be used for the anal yses of safet y variables. 
Per-protocol set (PPS) – it is a subset of the FAS which will consist of the patients who 
meet the following conditions:
No major deviations from the protocol procedures in the randomized treatment epoch
Have been exposed to study  medication for at least [ADDRESS_443679] 80% 
compliance on stud y medication.
Major protocol deviations will be pre-specified prior to unblinding treatment codes for 
analyses.
9.2 Patient demographics and other baseline characteristics 
Unless specified otherwise, baseline value is defined as the measurement obtained at the 
randomization visit date (Day  1), or the measurement obtained at an earlier visit (scheduled or 
unscheduled) which was closest to Day  1, if the Day  1 measurement is missing.
Summary  statistics will be provided by [CONTACT_146542], including age, age group (<65 years vs. ≥65 years; <75 years vs. ≥75 years), 
sex, race, ethnicity ,country , region, weight, height, body  mass index (BMI), education level, 
category  of prior CV medication, prior HF hospi[INVESTIGATOR_059], NYHA class, NT-proBNP, vital 
signs, MMSE overall summary score, MMSE categor y (<28, ≥28) , cerebrovascular disease 
burden factors as measured by [CONTACT_9268] (e.g. lacunar infarcts > 2; cortical or subcortical infarct > 
1cm3; white matter lesion Fazekas score of 3; micro he morrhages ≥4) and APO E4 allele status 
(carrier vs. non-carrier). BMI will be calculated as weight (kg) / height2(m2) from the 
collected height and weight at Visit 1 (Screening Visit). Continuous variables will be 

[COMPANY_001] Page 77
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
6. International Shoppi[INVESTIGATOR_220037] –delay ed recall (ISLT -DR) -Assesses verbal memory  
using the accuracy  (number of words recalled correctl y) of delayed recall in a verbal list 
learning paradigm
7. Groton Maze learning Test (GML T) – Assesses executive function using the number of 
total errors (number of error responses over 5 t rials) in a hidden pathway  maze learning 
paradigm
Standardized z- scores for each outcome measure and visit will be calculated using the sample 
baseline mean and standard deviation of individual tasks as follows:
ZDET= − (Log 10(DET) –baseline mean of log 10(DET))/SD of log 10(baseline DET), 
ZIDT= − (Log 10(IDT) –baseline mean of log 10(IDT))/SD of log 10(baseline IDT),
ZCPAL= (CPAL total errors – baseline mean of CPAL  total errors/SD of baseline 
CPAL  total errors), 
ZONB= − (Log 10(ONB) –baseline mean of log 10(ONB))/SD of log 10(baseline ONB), 
ZISLT= (ISLT –baseline mean of ISLT))/SD of baseline I SLT, 
ZISLT-DR= (ISLT-DR) –baseline mean of I SLT-DR))/SD of baseline ISLT- DR,
ZGMLT= − (GMLT –baseline mean of GMLT))/SD of baseline GMLT
Note that negat ive sign is included in the calculation for tasks where increasing values 
indicate worsening performance (i.e., ZDET, ZIDT, ZONB andZGMLT) so that for all standardized 
change scores negative values indicate a decline from baseline while positive scores indicate 
improvement from baseline.
These seven individual z -scores are then combined to generate the GCCS: 
CogState GCCS = average of (ZDET, ZIDT, ZCPAL, ZONB, ZISLT, ZISLT-DR, ZGMLT )
The composite score will be computed if five of the seven tests are completed and the five 
tests provide an assessment of the three cognitive domains as defined below being 
assessed. That is, a composite score requires that each cognitive domain be measured by [CONTACT_356267].
In addition to the GCCS, composite scores for three main subdomains memory , attention and 
psychomotor function will also be generated by [CONTACT_356268] :
Composite score of memory  tests = average of (ZCPAL, ZISLT, ZISLT-DR)
Composite score of executive function tests = average of (ZONB, ZGMLT)
Composite score of attention tests = average of (Z DECT, Z IDT)
Each composite score will be the average of the non- missing individual test z -scores
9.4.[ADDRESS_443680] battery  will be analyzed using a 
repeated measures analy sis of covariance (ANCOVA )model in which treatment, age 
stratification factor, MMSE stratif ication factor, education level, APOE4 status (carrier vs. 
non-carrier), baseline cerebrovascular disease burden as measured by [CONTACT_9268] (calculated based 
on four factors: lacunar infarcts > 2; cortical or subcortical infarct > 1cm3; white matter lesion

[COMPANY_001] Page 78
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Fazekas score of 3; micro hemorrhages ≥4), visit (Weeks 26, 52, 78, 104, 130 and Week 156) 
and treatment -by-visit interaction are included as fixed -effect factors and baseline GCCS and 
visit by [CONTACT_356269], with a common unstructured covariance 
matrix among visits between treatment group. The adjusted mean changes at 3 years (Week 
156) within each treatment, the difference in mean changes at 3 y ears (Week 156) between the 
two treatments, and its 95% confidence interval obtained from theabove model will be 
presented. In addition, the treatment difference (LCZ696
-valsartan) in mean changes from 
baseline to [ADDRESS_443681] size (Cohen’s d) with 
a 2-sided 95% confidence interval. The Cohen’s d will be estimated by [CONTACT_356270] -treatment mean difference, divided by [CONTACT_356271], which is 
calculated from the standard error of the adjusted mean change and the sample number of 
patients within each group (the pooled S D) from the above modeling. The anal ysis is based on 
likelihood method with an assumption of missing at random (MAR) for missing data.
As the primary  analysis, this repeated measure ANCOVA model will be performed in the 
Safety  set including ‘on-treatment’ data collected prior to the start of treatments for AD or 
cognitive impairment. The Cohen’s d based on the adjusted difference in mean changes at 3 
years (Week 156) between two treatments and its 95% confidence interval from this model 
will be used to draw the main conclusion for the primary  objective. On -treatment data refer to 
cognitive test data collected while patients are on-study -medication (regardless of treatment 
interruption) or within three months after final study  drug intake date.
In addition, the same repeated measure ANCOVA model will be performed in the following 
two anal ysis sets as supportive anal yses:
in the FA S, including all available data (even after treatment discontinuation and after 
start of treatments for AD or cognitive impairment)
in the per -protocol set, including ‘on -treatment’ data collected prior to the start of 
treatments for AD or cognitive impairment only.  
Summaries of absolute values and change from baseline in the GCCS and domain -specific 
composite z -scores by  [CONTACT_3148] g roup and visit will be presented. Figures will be produced to 
visually  show both the raw and the model -based mean global composite z- score sand mean 
domain -specific composite z -scores by  [CONTACT_356272]. These 
will be done in both the Safety  and FAS with the same data inclusion rules as for the above 
repeated measure ANCOVA modeling in the Safety  and FAS.
9.4.3 Handling of missing values/censoring/discontinuations
The repeated ANCOVA modeling as described in the previous section is based on likelihood 
method with an assumption of missing at random for missing data. That means, missing data, 
including those from dropouts, will be implicitly represented in the analy sis by [CONTACT_356273]. 
Data collected more than three months after patients permanent discontinuation of the study 
medication will be excluded from analyses in both the Safet y and PPS analy ses. In addition, 
data collected after patients starting treatments for AD or cognitive impairment will be 
excluded from “on -treatment” analyses.

[COMPANY_001] Page 79
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
For missing values at a specific post-baseline visit, any post-baseline unscheduled 
measurements taken within three -month window may  be re -mapped to this scheduled visit.
9.4.4 Sensitivity analy ses 
Although the MAR assumption is deemed appropriate choice for the primary  anal ysis, it is not 
possible to verify  its correctness based on the observed data ( CHMP, 2010 ,National Research 
Council, 2010). Indeed it is conceivable that censoring, respectivel y the missing data 
mechanism (e.g., due to death) may be informative and that the cognitive function decline in 
patients who died would have been steeper than estimated under the MAR assumption. Thus, 
the primary  analysis would favor the valsartan group in the presence of a reduction in 
mortality  in the L CZ696group.  
Due to this uncertaint y, analyses based on multiple imputations, such as those using a pattern
mixture model approach, will be performed to investigate the sensitivity  of the 
primar y 
analysis results based on the MAR assumption. These sensitivity  analyses assume that 
missing CogState test battery  scores after death, HF hospi[INVESTIGATOR_602], and stroke were missing 
not at random (MNAR).
Data censored at the start of treatments for AD or cognitive impairment may  be imputed using 
similar MNAR -based imputation approach. This analysis will be performed for the primary 
analysis in the Safet y set and for the supportive analysis in the FAS.   In addition, a shared 
parameter model (Vonesh et al 2006) to jointly  model longitudinal GCCS measurements and 
time to starting treatments for AD or cognitive impa irment will be further explored. This 
provides an analy sis of CogState test battery  scores that accounts for potential informative 
censoring due to starting treatments for AD or cognitive impairment. It should be noted that 
this joint modeling approach might fail to work or interpretation of the results may  be difficult 
if the incidence rate of patients starting treatment for AD or cognitive impairment in the 
present stud y is low.
To fully assess the effect of the missing data on the conclusions, an additional sensitivit y 
analysis will be performed for subjects with missing cognitive function measurements due to 
withdrawal for unknown reasons.
In addition, the following subgroup analyses will be performed for the primary  endpoint on 
the Safet y set including ‘on -treatment’ data collected prior to the start of treatments for AD or 
cognitive impairment. The analysis will be done using a similar repeated ANCOVA model as 
for the primary  analysis at individual subgroup level 
separatel y, while the p-values of the 
subgroup -by-treatment interaction will be derived from a similar model but with additional 
terms including the subgroup, the interaction term of subgroup -by-treatment. 
Age group (<65 vs. 
≥65 y ears), age group (<75 vs. ≥75 y ears) 
Gender (male/female) 
Region 
Education level
Baseline MMSE cut -off (<28, ≥28)
Baseline LVEF cut -off (<50%, ≥50 %)
Baseline NYHA class (II and III/IV)

[COMPANY_001] Page 80
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Baseline diabetes status (yes/no)
Baseline cerebrovascular disease burden as measured b y MRI
APOE4 allele status (carrier/non -carrier)
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables 
The secondary  variables are:
1.Change from baseline in individual cognitive domains (memory, executive function, and 
attention) as assessed b y the individual components of the cognitive assessment battery  at 
3 years;
2. Change from baseline in the summary score of the instrumental activities of daily  living 
(IADL) as assessed with Functional Activit y Questionnaire (FAQ) at 3 years.
The composite z- scores by [CONTACT_356274] (memory , executive function, and 
attention) are defined in Section 9.4.1.
For secondary  variables composite 
z-scores by [CONTACT_356275] (memory , executive 
function and attention) and I ADL, the changes from baseline to3 years will be analy zed using 
the same repeated measures ANCOVA model as described in Section 9.4.2 but with baseline 
GCCS replaced with respective secondary  variable baselines. The adjusted mean changes at 3 
years (Week 156) within each treatment, the difference in mean changes at 3 y ears (Week 156) 
between two treatments, its 95% confidence interval obtained from the above model will be 
presented. The analysis is based on likelihood method with an assumption of missing at 
random for missing data, and will be performed in the Safety  set including ‘on -treatment’ data 
collected prior to the start of treatments for AD or cognitive impairment. On-treatment data 
are those collected while patients are on-study -medication (regardless of treatment 
interruption) or within three months after final study  drug intake date. This analysiswill be 
performed in the SAF.
In addition, as supportive analysis, similar repeated measure ANCOVA model will be also 
performed for these secondary endpoints for a ll data in the FAS.
Summaries of absolute values and change from baseline by [CONTACT_356276]. Figures will be produced to visuall y show the endpoint values (SUVr, composite z -
scores by  [CONTACT_356277]) by  [CONTACT_356278] e study  period for each treatment group.
These analyses will be done in both SAF and FAS, for ‘on-treatment’ data and for all data, 
respectivel y.
For these secondary  variables, a three month window will be applied to re-map any 
unscheduled visit assessment s to a missing scheduled visit assessment.
9.5.2 Safety  variables 
Safety  evaluations to be anal yzed are listed as below:
Change from baseline in a cortical composite SUVr (standardized uptake value ratio) at 3 
years 

[COMPANY_001] Page 82
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
may be performed, which assumes that missing values after death, HF hospi[INVESTIGATOR_602], stroke 
were missing not at random (MNAR).
A shift table to summarize the proportion of patients’ amyloid status change over time from 
baseline b y treatment will be provided as we ll.
All analy ses will be performed in patients in the Safety  set who participate in the PET image 
sub
study , including ‘on-treatment’ data only. On-treatment data refer to the SUVr values 
obtained while patients are on-study -medication (regardless of treatm ent interruption) or 
within sixmonths after final study  drug intake date.
9.5.3 Resource utilization 
Not applicable
9.5.4 Pharmacokinetics 
Not Applicable

[COMPANY_001] Page 84
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320

[COMPANY_001] Page 85
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320

[COMPANY_001] Page 86
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
9.7 Interim analy ses
No formal interim efficacy  analyses areplanned. Refer to Section 8.4 for planned regular 
interim safet y data review by [CONTACT_23275].
9.8 Sample size calculation
9.8.1 Sample size calculation for the primary  endpoint
It is currentl y estimated that approximately 180 patients per group 
would provide at least 80% probability  that the 2 -sided 95% confidence i nterval ( CI)  
excludes a standardized effect size (Cohen’s d) of 0.3 (or gr eater) in change in composite 
z-score of the battery  test over 3 y ears, given that there is no expected difference between 
two treatments. 
Would provide at least 80% probability  that the 2 -sided CI  excludes 0 (corresponding to 
p<0.05), if the true effect size is 0.3 or greater (in either direction).
An effect size of 0.3 in Cohen ’sd corresponds to amargin of 0.3xSD(SD=standard deviation)
on the original scale for the difference between treatments in mean global score change from 
baseline , and is generally considered as small ( Cohen 1988 ). In a systematic review of studies 
for health -
related quality  of life instruments that have reported the minimally  important 
difference (MID), it was found that for the majority  of studies the MID estimates were 
consistently  close to 0.5xSD(Norman et 
al 2003 ).In addition, sociall y accepted benchmarks 
for conditions that induce cognitive impairment such as low level alcohol intoxication within 
legal driving limit in most countries (0.05%) are generall y associated with declines of 0.[ADDRESS_443682] (or exclude) effect sizes in the magnitude of 0.3 
in Cohen’s d with high probability , as it appear s to be an appropriate choice to guide the 
interpretation of the cognitive function results. 
In addition, defining the magnitude of the MID using a measure of effect size, rather than a 
raw difference score has additional advantages:
Expressing the magnit ude of an important difference in scale free units (Cohen’s d) allows 
models of clinically  meaningful difference to be based on integration of outcomes from a 
broad set of studies whose characteristics are relevant to the current study  (i.e. magnitude 
of change in cognition related to amy loid, magnitude of change oc curring after heart 
failure , and magnitude of change related to cardiovascular disease ). 
Estimates of clinically  meaningful difference can be referenced to the magnitude of 
cognitive decline detected from studies where compounds with accepted central nervous 
system adverse effects, at known doses are administered to older adults (e.g. scopolamine, 
alprazolam).
Sample size calculation was performed using N -Query  7.0.
9.8.2 Sample size calculation for the PET imaging substudy  
Approximately  300 patients (in 1:1 allocation ratio to LCZ696 and valsartan) will provide at 
least 80% probability  that 
the 2-sided 95% CI excludes a between -treatment absolute 

[COMPANY_001] Page 87
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
difference of 0.01 (corresponding to an incremental 33% increase in LCZ696 vs. valsartan) in 
change from baseline in SUVr over [ADDRESS_443683] deviation is 0.03 
(estimated from ADNI data, Chen et al 2015). It is noted that the ADNI  data presented in 
Chen’s paper are by [CONTACT_1962]’ cognitive status (normal, MCI , dementia) and for changes over 
two years. The assumptions used here 
are guestimates from the 2 year data in normal 
cognitive and MCI  subjects.
An absolute difference in SUV ratio of 0.01 was considered small as itrepresents a value that 
is lower than the rate of SUVr change that distinguishes between amyloid positive and 
negative patients (0.026 vs. 0.011).  
Sample size calculation was performed using N -Query  7.0.
9.8.3 Blinded sample size r e-estimation
Approximately 520 patients will be randomized in order to provide overage to account for the 
information loss caused by [CONTACT_159641] 30% “drop -out” (including death, lost-to-follow -up, 
permanent discontinuation of study  medication and start of treatments for AD or cogn itive 
impairment) during 3 year period.  In the PET imaging substudy  approximately 430 patients
will be randomized.
A loss of 30% of information is acrude estimate therefore it is planned to monitor the ‘drop -
out’ pattern as the trial is ongoing in order to provide a better prediction of the information 
loss for a given number of patients.  The final number of patients randomized may  be reduced 
if there is sufficient evidence that the information loss will be less than 30% and that the 
precision of the estimates of treatment effect (as described in the sample size section above), 
will be maintained.
10 Ethical considerations 
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and 
Japanese Ministry  of Health, L abor, and Welfare), and with the ethical principles laid down in 
the Declaration of Helsinki.
10.2 Informed consent procedures 
Eligible patients/subjects may only  be included in the study  after providing written (witnessed, 
where required by [CONTACT_6617]), IRB/IEC -approved informed consent . He/she must 
indicate assent by[CONTACT_233632] a 
separate assent form. Informed consent must be obtained before conducting any  study -specific 
procedures (e.g.all of the procedures described in the protocol). The process of obtaini ng 
informed consent must be documented in the patient source documents. 

[COMPANY_001] Page 89
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
11 Protocol adherence 
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of patients/subjects
should be administered as deemed necessary  on a case by [CONTACT_413]. Under no circumstances 
is an investigator allowed to collect additional data or conduct any additional procedures for 
any research related purpose involving any  investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and health authorities, where required, it cannot be 
implemented. 
11.[ADDRESS_443684] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediate 
hazard to patients/subjects may be implemented immediately  provided the health authorities
are subsequently  notified by [CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , 
even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section [ADDRESS_443685]
Ampadu J, Morley  JE (2015) Heart failure and cognitive dy sfunction. Int J Cardiol; 178:12 -23.
Arslanian- Engoren C, Giordani BJ, Algase D, et al (2014) Cognitive dy sfunction in older 
adults hospi[INVESTIGATOR_356214]. J Card Fail; 20:669 -78.
Bateman RJ, Xiong C, Benzinger TLS, et al (2012) Clinical and biomarker changes in 
dominantly  inherited Alzheimer’s disease. N Engl J Med; 367(9):795-804.
Bauer LC, Johnson JK, Pozehl BJ (2011) Cognition in heart failure: An overview of the 
concepts and their measures. J Amer Acad Nurse Practition; 23:577-85.
Belleville S, Fouquet C, Duchesne S, et al (2014) Detecting earl y Alzheimer’s Disease via 
cognition, neurops ychiatry , and neuroimaging: Qua litative review and recommendations for 
testing. J Alzheimers Dis; 42:S375
-82.
Cannon JA, McMurray  JJ, Quinn TJ (2015) “Hearts and minds”: association, causation, and 
implication of cognitive impairment in heart failure. Alz Res Ther; 7:22.
Cash DM, Frost C, Iheme LO, et al (2015) Assessing atroph y measurement techniques in 
dementia: Results from the MI RIAD atrophy  challenge. Neuroimage; 123:149-64.

[COMPANY_001] Page 90
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Castilla -Rilo J, L ópez -Arrieta J, Bermejo- Pereja F, et al (2007) Instrumental activities of daily  
living in t he screening of dementia in population studies: a sy stematic review and meta -
analysis.IntJ Geriatr Psy chiatry ;22:829 -36.
Cavalieri M, Enzinger C, Petrovic K, et al (2010) Vascular dementia and Alzheimer’s Disease 
–are we in a dead end road? Neurodegene rative Dis; 7:122 -6.
Chen K, Roontiva A, Thiyyagura P, et al (2015) Improved power for c haracterizing 
longitudinal amyloid-β PET c
hanges and e valuating amyloid-modify ing treatments with a 
cerebral w hite m atter reference region. J Nucl Med; 56(4):560-6.
Chou CC, Pressler SJ, Giordani B, et al (2015) Validation of the Chinese version of the 
CogState computerized cognitive assessment battery in Taiwanese patients with heart failure. 
J Clin Nurs; 24:3147-54.
Clark AP, McDougall G (2006) Cognitive impairment in heart failure. Dimens Crit Care Nurs;
25(3) :93- 100.
Cleland GF, Tendera M, Adamus J (2006) The perindopril in elderly  people with chronic 
heart failure (PEP -CHF) study . Eur Heart J; 27:2338 -45.
Cohen J (1988) Statistical Power Anal ysis for the Behavioral Sciences. 2ndEdition New 
Jersey : Lawrence Erlbaum Associates.
Collie A, Darb y DG, Falleti MG, et al (2002) Determining the extent of cognitive change after 
coronary  surgery : a review of statistical procedures. Ann Thorac Surg; 73:2005 -11.
Committee for h uman medicinal products (CHMP), European Medicines Agency  (EMA). 
(2004) ICH Topic E2D: Post approval safety data management, London, [LOCATION_006].
Committee for Medical Products for Human Use. Guideline on missing data in confirmatory  
clinical trials. L ondon: Europe an Medicines Agency , July  2, 2010. 
http://www.ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2010/09/WC5
00096793.pdf
.(Accessed 5 Apr il2016).
Corder EH, Saunders AM, Strittmatter WJ, et al (1993) Gene dose of apolipoprotein E ty pe 4 
allele and the risk of Alzheimer's disease in late onset families. Science; 261:921 -3.
Darb y DG, Brodtmann A, Pi[INVESTIGATOR_41279], et al (2011) Epi[INVESTIGATOR_356215] -dwelling older adults. J Alzheimers Dis; 27:627 -37.
Desa i AS, Lewis EF, Li R, et al (2011) Rationale and design of the treatment of preserved 
cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled 
study  of spi[INVESTIGATOR_356216]. Am Heart J; 162:966-72.
Donohue MC, Sperling RA, Salmon DP (2014) The preclinical Alzheimer cognitive 
composite: measuring amy loid-related decline. JAMA Neurol; 71(8) :961- 70.
Fogari R, Mugellini A, Zoppi A (2004) Effects of valsartan compared with enalapril on blood 
pressure and cognitive function in elderly  patients with essential hypertension . 
Eur JClin Pharmacol; 59:863 -8.
Gorelick PB, Ny enhuis D (2012) Blood pressure and treatment of persons with hy pertension 
as it relates to cognitive outcomes including executive function. J Am Soc Hy pertens;
6(5):309- 15.

[COMPANY_001] Page 93
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Simoni D, Rafanelli M, Ungar A, et al (2014) Neurocognitive profile of patients with 
continuous flow left ventricular assist device. Mo naldi Arch Chest Dis; 82(2):75-9.
Skoog I, Lernfelt B, Landahl S, et al (1996) 15 -year longitudinal stud y of blood pressure and 
dementia. Lancet; 347: 1141-5.
Snyder PJ, L im YY, Schindler R, et al (2014) Microdosing of scopolamine as a “cognitive 
stress test”: rationale and test of a very  l
ow dose in an at-risk cohort of older adults. 
Alzheimers Dement; 10:262 -7.
Steinberg SI, Sammel MD, Harel BT, et al (2015) Exercise, sedentary  pastimes, and cognitive 
performance in healthy  older adults. Am J Alzheimers Dis Other Demen; 30(3) :290- 8.
Stevens L A, Coresh J, Greene T, Levey  AS (2006) Assessing kidney  function –measured and 
estimated glomerular filtration rate. N Engl J Med; 354:2473-83.
Teng E, Becker BW, Woo E, et al (2010) Utility  of the functional activities questionnaire for 
distinguishing mild cognitive impairment from very  mild Alzheimer’s disease. Alzheimer Dis 
Assoc Disord; 24(4):348-53.
Thomas E, Sny der PJ, Pi[INVESTIGATOR_41279], et al (2008) Specific impairments in visuospatial working 
and short -term memory  following low -dose scopolamine challe nge in healthy  older adults. 
Neurops ychologia; 46:2476 -84.
Vellas B, Bateman R, Blennow K, et al (2015) Endpoints for pre- dementia AD trials: A report 
from the EU/US/CTAD Task Force. J Prev Alzheimers Dis; 2(2) :128- 35.
Vemuri P, Jack CR (2010) Role of stru ctural MRI in Alzheimer’s disease. Alzheimers Res 
Ther; 31:23 -33.
Villemagne VL, Burnham S, Bourgeat P, et al (2013) Amy loid β deposition, 
neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective 
cohort study . Lancet Neurol; 12:357 -67.
Villemagne VL, Pi[INVESTIGATOR_356217], Chételat G, et al (2011) Longitudinal assessment of A β and 
cognition in aging and Alzheimer disease. Ann Neurol; 69(1):181-92.
Vonesh EF, Greene T, and Schluchter MD (2006) Shared parameter models for the joint 
analysis of longitudinal data and event times. Stat Med;25(1) : 143-63.
Wang DS, Dickson DW, Malter JS (2006) β -Amy loid degradation and Alzheimer's disease. J 
Biomed Biotechnol; 2006:
1-12.
Yusuf S, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart 
failure and preserved left- ventricular ejection fraction: the CHARM -Preserved trial. Lancet; 
362:777-81.
Zuccala G, Onder G, Marzetti E, et al (2005) Use of angiotensin- converting enz yme inhibitors 
and variations in cognitive performance amo ng patients with heart failure. Eur Heart J;
26(3) :226- 33.

[COMPANY_001] Page 94
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320

[COMPANY_001] Page 95
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
14 Appendix 2: Liver event definition and follo w-up 
requirements
Table 14-1 Liver event d efinitions
Definition/ threshold
AE of special interest
Laboratory valuesALT or AST > [ADDRESS_443686]
ALP > [ADDRESS_443687]
TBL > 1.[ADDRESS_443688]
Medically significant event 
(SAE)
Laboratory values ALT or AST > [ADDRESS_443689] 
(with or without TBL > [ADDRESS_443690] [mainly conjugated fraction])
ALP > [ADDRESS_443691] 
(with or without TBL > [ADDRESS_443692] [mainly conjugated fraction])
TBL > [ADDRESS_443693]
Potential Hy’s Law cases (defined as ALT/AST > [ADDRESS_443694] and TBL > [ADDRESS_443695] 
[mainly conjugated fraction] without notable increase in ALP to > [ADDRESS_443696]
AEs Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, abdominal 
pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
TBL: total bilirubin; ULN: upper limit of normal 
Table 14-2 Follo w up requirements for liver e vents 
Criteria Event type Actions required Follow -up monitoring
Potential Hy’s 
Law caseaMedically 
significantDiscontinue the study drug immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Report to [COMPANY_001] as an SAE
Establish causalityALT, AST, TBL, Alb, PT, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
ALT or AST
> [ADDRESS_443697], TBL, Alb, PT, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 5 to ≤ [ADDRESS_443698], TBL, Alb, PT, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
>[ADDRESS_443699], TBL, Alb, PT, ALP 
and γGT until resolutionc
(frequency at invest igator 

[COMPANY_001] Page 96
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Criteria Event type Actions required Follow -up monitoring
Establish causality discretion)
> 3 to ≤ [ADDRESS_443700] 
(patient is 
asymptomatic)Adverse event 
of special 
interest ( AESI )Central laboratory to report to Investigator 
& [COMPANY_001]
Repeat LFT once or twice in the week
If elevation persists, establish causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
≤ [ADDRESS_443701] 
(patient is 
asymptomatic)N/A Repeat LFT at next visit
ALP (isolated)
> [ADDRESS_443702] Medically 
significantRepeat LFT within 48 hours
If elevation persists, report to [COMPANY_001] as 
an SAE
Establish causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
> 2 to ≤[ADDRESS_443703] 
(patient is 
asymptomatic)AESI Central laboratory to report to Investigator 
& [COMPANY_001]
Repeat LFT once or twice in the week. If 
elevation persists, establish causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
≤ 2 x UL N
(patient is 
asymptomatic)N/A Repeat LFT at next visit
TBL (isolated)
> [ADDRESS_443704], TBL, Alb, PT, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
Test for hemolysi s (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ [ADDRESS_443705]
(patient is 
asymptomatic)AESI Central laboratory to report to [COMPANY_001]
Repeat LFT once or twice in the week. If 
elevation persists, establish causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
≤ 1.[ADDRESS_443706]
(patient is 
asymptomatic)N/A Repeat LFT at next visit
Preferred terms
Jaundice Medically 
significantDiscontinue the study drug immediately
Hospi[INVESTIGATOR_351960], AST, TBL, Alb, PT, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
“Drug -related 
hepatic 
disorders -
severe events 
only” SMQ AEMedically 
significantDiscontinue the study drug 
Hospi[INVESTIGATOR_356218]/AST > [ADDRESS_443707] and TBL > [ADDRESS_443708] but with no notable increase in ALP to > [ADDRESS_443709]
bGeneral malaise, fatigue, abdominal pain, n ausea, or vomiting, rash with eosinophilia
cResolution is defined as an outcome of one of the following: return to baseline values, stable values at three 
subsequent monitoring visits at least 2 weeks apart, remain at elevated level after a maximum of 6 m onths, liver 
transplantation, and death.

[COMPANY_001] Page 97
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
15 Appendix 3: Treatment guidelines for hy perkalemia (serum 
potassium greater than or equal to 5.3 mmol/L [mEq/L])
General principles
Elevation of potassium levels above the predefined values should be repeated and confirmed 
before any action is taken.
Any patient with a serum potassium > 5.3 mmol/L  (mEq/L) at any time after randomization 
requires the Investigator to confirm the potassium concentration in a non-hemoly zed sample 
via an immediate repeat lab sample to both the clinic local lab and the study  central lab.  
Regular, repeated checks of potassium concentration (beyond that prescribed in the protocol) 
should continue until it is clear that the potassium concentration is stable and not rising into 
the range of concern (≥ 5.5 and < 6.0 mmol/L  [mEq/L ]) or potential danger (≥ 6.0 mmol/L 
[mEq/L ]). 
Patients with elevated potassium value will be managed according to the corrective actions 
outlined below. Hy
perkalemia should be followed until resolution.
Corrective ac tion for management of hy perkalemia
Serum potassium greater than 5.3 and less than or equal to 5.5 mmol/L (mEq/L)
Confirm potassium concentration in a non -hemoly zed sample
Reinforce low potassium diet and restriction of food/drinks with high potassium cont ent 
(e.g.,orange juice, melon, bananas, tomatoes, dried fruits, potatoes, low -salt substitutes, 
tomatoes, coffee, etc.) 
Correct metabolic acidosis if necessary . 
Review medical regimen (including dietary  supplements and over -the-counter medications) 
for agents known to cause hy perkalemia. Consider reduction in dose or discontinuation of 
these agents:
1.MRAs (if they  are believed to be the most likely  cause of h yperkalemia)
2.Potassium -sparing diuretics (e.g. ,amiloride and triamterene) including in combinatio n 
products with thiazide or loop diuretics 
3. Potassium supplements, e.g., potassium chloride
4.Salt substitutes 
5.Non-steroidal anti -inflammatory  drugs (NSAIDs)
6.Cyclo-oxygenase -2 (COX -2) inhibitors
7.Trimethoprim and trimethoprim -containing combination products, such as Bactrim®
and Septra®(trimethoprim/sulfamethoxazole fixed combination)
8.Herbal Supplements:
For example, Noni juice, alfalfa ( Medicago sativa ), dandelion ( Taraxacum officinale ), 
horsetail ( Equisetum arvense ), nettle ( Urtica dioica ), milkweed, lily of the valley , 
Siberian ginseng, hawthorn berries

[COMPANY_001] Page 98
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
Assess patient for deh ydration or any  condition that could lead to deh ydration (e.g., 
diarrhea, vomiting) and/or hy povolemia and initiate appropriate corrective measures of 
rehydration. 
Repeat serum potassium measurement within 3 to 5 day s
If serum potassium remains > 5.3 and ≤ 5.5 mmol/L (mEq/L), regularly  monitor serum 
potassium levels to ensure stability  (suggested once monthly )
Consider down- titration of study  drug, according to investigator’s medical judgment.
Serum potassium greater than 5.5 and less than 6.0 mmol/L (mEq/L)  
Confirm potassium concentration in a non -hemoly zed sample 
Consider down- titration or temporaril y discontinue study  drug according to investigator 
medical judgment. 
Apply  all me asures outlined for serum potassium > 5.3 and ≤ 5.5 mmol/L
Repeat serum potassium measurement after 2 -3 day s
If serum potassium < 5.5 mmol/L , consider resumption of study  drug at lower dose with 
repeat potassium within 5 days
Serum potassium greater than o r equal to 6.0 mmol/L (mEq/L)
Immediately  discontinue study  drug
Confirm potassium concentration in a non -hemoly zed sample
Urgently  evaluate patient and treat hy perkalemia as clinically  indicated 
Apply  all measures outlined for serum potassium > 5.3 and < 6.0 mmol/L  (mEq/L )
No resumption of study  drug without individualized case discussion with and permission from 
[COMPANY_001] medical monitor or his/her designee.

[COMPANY_001] Page 99
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
16 Appendix 4: Guidelines for the management of blood 
pressure
Guidelines
1.Investigator should monitor BP closel y 
2.If symptomatic hy potension occurs:
a.Correct an y treatable cause, e.g. h ypovolemia
b.If hypotension persists, any antih ypertensive drug such as diuretics, calcium channel 
blockers (CCBs), nitrates, beta blockers, aldosterone antagonists and α- blockers, 
should be down -titrated or stopped first before down- titration of the study  drug is 
considered. An y non -antihy pertensive drug (such as nitrates) should be considered for 
down -titration prior to study  drug as determined by  [CONTACT_356279].
c.If hypotension persists, the study drug should be down -titrated or even temporarily  
withdrawn. The dose re -challenge and medications adjust guidelines described in 
Section 5.5.5 should be adhered to as much as possible.

[COMPANY_001] Page 100
Amended Clinical Trial Protocol Version 0 2  (Clean ) Protocol No. CLCZ696B2320
17 Appendix 5: Guidelines for the management of renal 
dysfunction
General principles:
Glomerular filtration rate in HF patients depends on intrinsic renal function and on a balance 
between afferent and ef ferent glomerular arterial tonicity . This tonicity  is partly  regulated by  a 
stimulation of angiotensin II and could be affected by [CONTACT_356280]. Moreover, renal 
dysfunction may develop or may deteriorate in some patients after study  drug administration. 
These recommendations have been developed to guide the investigators in managing patients 
with renal d ysfunction after randomization.
Two types of response to serum creatinine increase are described:
Surveillance situation 
If, at any time after randomi zation, eGFR decreases by ≥25% from baseline (Visit 1) (or if 
serum creatinine concentration increase to 2.5 mg/dL [221 µmol/L ]), the investigator will 
check for potentiall y reversible causes of renal d ysfunction such as:
Non-steroidal anti -inflammatory  drug intake, antibiotics, or other treatments known to 
affect creatinine
Volume decrease, including that resulting from excessive dosing of diuretics
Urinary  infection
Urinary  tract obstruction
Study  drug
Action situation 
If a patient’s eGFR decreases by ≥40% from baseline (Visit 1) (or if serum creatinine 
concentration rises above 3 mg/dL (265 µmol/L ), the investigator will check for potentiall y 
reversible causes of renal dy sfunction (see above).
The investigator may consider down -titration of study  drug. If the investigator judges that 
study  drug has to be stopped, he/she will have to contact [CONTACT_356281]/her designee. Thereafter, serum creatinine assessments will have to be repeated at least 
each week until levels return to acceptabl e values. If study drug was stopped, every  effort will 
be done to restart it again, according to clinical conditions.
